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Metastasis is the main cause of death in breast cancer patients; however, there 
are currently no treatments available to treat or prevent metastasis. This is in part 
because regulators of metastasis are not yet fully understood. Over the past century 
researchers began to study metastasis regulators by different hypotheses, such as the 
seed and soil hypothesis which focuses on studying the role of cancer cells, the seeds, and 
the tissue microenvironment, the soil, in regulating metastasis. Although lots of studies 
have focused on the microenvironment of metastatic sites and their roles in regulating 
metastasis, limited studies have focused on the role of the primary tumor 
microenvironment in regulating metastasis. Thus, investigating the role of the primary 
tumor microenvironment will provide more insight on metastatic regulators which may 
lead to the development of new therapeutic strategies to treat or prevent metastasis.  
The aim of this study is to evaluate the role of primary tumor microenvironment 
in regulating metastasis using a triple negative breast cancer mouse model. Mammary 
glands contain two distinct microenvironments, soils: epithelium and stroma. Human 
breast cancer originates in the epithelial microenvironment of the mammary glands; 
however, researchers are using stromal microenvironment to generate mammary tumors 
and bypassing the epithelium. Therefore, we first tested if the epithelial 
v 
microenvironment has an effect on tumor progression and/or metastasis when compared 
to stromal microenvironment. We chose the widely used 4T1 mouse model and delivered 
the 4T1 cells intraductally into the epithelium.  Our results show that the primary tumor’s 
epithelial microenvironment promotes more aggressive tumors compared to the stromal 
microenvironment.   
Knowing that mammary glands exhibit left-right differences in epithelial and 
stromal gene expression, we next investigated the role of left versus right epithelial 
microenvironment in regulating metastasis. Here we show that the right epithelial 
microenvironment more effectively supports M2- like macrophage polarization which 
promotes more aggressive 4T1 cells and increased metastatic behavior. Furthermore, we 
tested if the left and right mammary tumor microenvironments have differences in 
therapeutic response against Emodin, a Chinese herb that targets M2- like macrophage 
polarization. Emodin treatment more effectively reduces metastasis in the right tumor 
group, while emodin treatment has no effect on the left tumor group. Taken together, 
our data indicates for the first time that the left and right mammary tumor 
microenvironments are different in metastatic support and therapeutic response.
vi 
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1.1. Breast Cancer Metastasis  
Breast cancer is the second cause of cancer related death in women. However, 
the main cause of breast cancer mortality is metastasis. The American Cancer Society 
(ACS) states that patients with metastatic breast cancer have poorer survival rates than 
patients at earlier stages of cancer development (1). However, no treatment is currently 
available to prevent or treat metastasis. This is in part because the regulators of 
metastatic processes are not yet fully understood.  
Breast cancer becomes metastasized when it spreads beyond the part of the body 
where it originated. During metastasis, cancer cells break away from the primary tumor 
and undergo multiple processes that lead to the formation of secondary tumors in distant 
parts of the body. From primary tumors to form secondary tumors, cancer cells need to 
go through sequential events called the metastatic cascade including invasion, 
intravasation, extravasation, and colonization (2). The process of invasion starts once 
cancer cells break away from the primary tumor mass. The detached cancer cells invade 
the basement membrane and migrate through the surrounding stroma to reach the 
nearby circulatory vessels in breast tissue. Cancer cells then intravasate as they penetrate 
the lymphatic or vascular wall and travel through the circulation system. The traveling 
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cancer cells then extravasate by invading the vascular wall into distant organs. Ultimately, 
the cancer cells proliferate and form new tumors in their new location in processes called 
colonization. The successful completion of the metastatic process is determined by the 
ability of cancer cells to colonize in the distant organs (3, 4).  
Over the past century, studies have been investigating regulators of metastasis 
through different hypothesis such as the seed and soil hypothesis proposed by Stephen 
Paget in 1989. Paget suggested that the metastatic cascade is highly controlled by two 
main factors: the seeds, cancer cells, and the soil, the tissue microenvironment (5). This 
section will review the seed and the soil of breast cancer, focusing on the role of 
mammary soil in regulating metastasis.  
1.1.1. Breast Cancer Cells: “The Seeds”   
 Breast cancer is a complex disease that is derived from the epithelial components 
of the mammary gland. Breast cancer can initiate from different mammary epithelial cells 
including: stem cells, luminal progenitor, or luminal differentiated cells (6, 7). Emerging 
evidence indicates that the origin of cancer cells may define the molecular and the cellular 
content of the resulting tumor (8, 9). Breast cancer can be classified into six molecular 
subtypes: luminal A, luminal B, basal like, HER2+ enriched, normal breast and claudin-low 
(10-12). Another classification of breast cancer is based on the hormonal receptor 
expression by cancer cells: estrogen receptor positive (ER+), human epidermal growth 
factor receptor 2 overexpressing (HER2+), and triple negative. For example, normal-like 
and triple negative subtypes initiate from mutated mammary stem cells, whereas 
mutations in luminal progenitor cells give rise to luminal B and HER2+ subtypes(13). The 
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association between breast cancer subtype and metastatic activity has been documented 
(14, 15). For example, studies have showed that the ER+ subtype is more likely to 
metastasize to the bone, while HER2+ and triple negative subtypes metastasize to the 
lung and liver (13, 16, 17).    
1.1.2. Mammary Microenvironment: “The Soil” 
The mammary gland is composed of two main components: the epithelium (ductal 
network) and the stroma (fat pad), separated by the basement membrane. The mammary 
microenvironment is composed of complex interactions between the epithelium and the 
stroma (18, 19). Within the epithelial component, there are two distinct cell types: luminal 
cells and basal cells which produce and attach to the basement membrane. Each cell type 
further contains subpopulations of cells with different levels of differentiation. The 
luminal compartment is composed of luminal progenitor cells and differentiated luminal 
cells (20-23). The basal compartment is composed of mammary stem cells, myoepithelial 
progenitor cells, and differentiated myoepithelial cells (24, 25).  The ductal network is 
formed by an outer layer of basal cells and an inner layer of the luminal cells. The 
mammary ducts are surrounded by the stroma comprised of multiple components 
including: adipocyte, fibroblast, immune cells, blood vessel, and extracellular matrix (18, 
19, 26).   
The mammary microenvironment is increasingly recognized as a major regulator 
of normal and cancer development. During normal development, mammary glands 
undergo different developmental stages: embryonic, puberty, pregnancy, lactation, and 
involution.  The epithelial component of the mammary gland arises from the mammary 
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placodes which are derived from the ectoderm (27, 28). Mammary placodes then grow 
into the primary mammary duct or rudiment. Meanwhile, the stroma is derived from 
dermal mesenchyme. The formation of mammary ducts from the placodes is highly 
controlled by the surrounding mesenchymal signaling (29, 30). The epithelial ducts then 
undergo rapid growth during puberty. Ovarian hormones and growth factors signal from 
stromal components initiate growth and differentiation of the epithelial cells within the 
primary ducts (19, 31). In addition to the stromal signals, studies have shown that 
epithelial differentiation is also regulated by the epithelial subpopulation within the ducts 
(32, 33). Then, the epithelial cells undergo cycles of proliferation and apoptosis during 
late developmental stages (pregnancy, lactation, and involution) followed by proliferation 
and remodeling of the stromal component (34, 35). Taken together, the mammary 
microenvironment controls the mammary gland during multiple different normal 
developmental stages.  
1.2. Role of Mammary Microenvironment in Metastasis 
When neoplasia occurs, cancer cells interact with the local microenvironment to 
create a new framework that supports tumor growth, called the tumor 
microenvironment. Studies suggest that interactions between cancer cells and the local 
tissue microenvironment determine metastatic behavior.  In addition to cancer cells, the 
tumor microenvironment is composed of multiple distinct cell types including the normal 
mammary cells and recruited cells such as immune cells. The non-malignant cells within 
the tumor microenvironment are called tumor-associated cells and are known to be 
active participants in tumor progression and metastasis. Through interactions with 
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tumor-associated cells, cancer cells undergo genetic modifications which enable them to 
disseminate from the primary tumor and invade surrounding tissue (36).  
Dissemination or detachment of cancer cells from the primary tumor mass is the 
initial step for the metastatic cascade. Dissemination is found to be tightly associated with 
epithelial-mesenchymal transition (EMT), a process in which epithelial cells undergo 
multiple changes to gain mesenchymal properties during embryogenesis. Increasing 
evidence shows that the tumor microenvironment stimulates EMT in cancer cells through 
the activation of the same pathways as those activated during embryogenesis. EMT, 
embryonic and in cancer cells, is characterized by loss of E-cadherin which results from 
mutations in the E-cadherin gene that disrupt its function. Also, losing E-cadherin can 
result from decreasing its expression as a subsequent step for the activation of 
transcriptional factors such as Snail, Slug, Twist and FOXC2. Moreover, studies in colon 
cancer show that decreasing E-cadherin gene expression and stimulating EMT in cancer 
cells can also be mediated by TGFβ signaling. TGFβ-induced EMT is found to be triggered 
by TNF-α produced by infiltrated macrophages (37, 38). Furthermore, the disruption of E-
cadherin is associated with expressions of N-cadherin, mesenchymal cadherin, which 
facilitates motility and migration of cancer cells within the surrounding stroma (39).   
During migration, stroma-associated cells regulate tumor cell invasion through 
different signaling pathways. For example, mesenchymal stem cells can stimulate 
invasion behavior in cancer cells through CCL5 production. It is found that CCL5 promotes 
the secretion of metalloproteinase MMPs which act by breaking down the extra cellular 
matrix (ECM), thereby increasing the motility of cancer cells (40). Also, tumor-associated 
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macrophages (TAMs), another stroma-associated cells, promote cancer cell invasion 
through the secretion of epidermal growth factor and producing matrix-degradation 
enzymes such as MMPs (41). The tumor microenvironment then supports tumor cells 
intravasation and survival through the vascular system. Experimental evidence has shown 
that macrophages help tumor cells to intravasate into the blood vessel through their 
interactions with endothelial barriers (42). Extravasation and secondary tumor formation, 
the final steps of the metastatic cascade, are found to be highly regulated through tumor 
microenvironment signaling (43). It is suggested that the tumor microenvironment 
regulates cancer cells colonization in distant organs through pre metastatic signaling (44). 
Taken together, the tumor microenvironment is pivotal in each step of metastatic 
cascade. Therefore, understanding the role of mammary microenvironment in metastasis 
is crucial step to developing new therapeutic targets.   
1.3. Limitation in Understanding Role of Mammary Microenvironment in Metastasis 
The role of the microenvironment in tumor progression and metastasis has been 
investigated over the past years. However, these studies are either correlative or limited 
to specific components of the microenvironment. While the mammary microenvironment 
is composed on two main component, most studies have been focusing only on the role 
of the stromal component in regulating metastasis (45). One of the reasons is that studies 
are using breast cancer mouse models where tumors are generated within the mammary 
stroma (fat pad) and bypassing the epithelium. In an attempt to overcome this limitation, 
we will be including the epithelial components when studying the role of tumor 
microenvironment by generating tumors intraductally.   
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It has been shown that the epithelial component plays a crucial role in regulating 
cell fate. Experimental studies indicate that mammary epithelial cells can redirect somatic 
cells from other organs (testes and nerve) as well as transformed cells into cells that form 
a functional mammary outgrowth (46-49). Therefore, failure to consider effects of the 
epithelial component may be a significant omission in understanding the role of the 
mammary microenvironment in metastasis. Moreover, human breast cancer originates 
within the epithelial microenvironment and then interacts with the stroma. Therefore, 
we hypothesize that the epithelium plays a role in regulating the breast cancer metastatic 
cascade which has not yet been studied. This hypothesis will be tested in chapter 2.     
1.4. Role of Macrophages in Breast Cancer 
In breast cancer, the immune cell component of tumor microenvironment plays a 
crucial role in regulating tumor progression and metastasis. Tumor associated 
macrophages are the major immune cells in the tumor microenvironment (50, 51). 
Macrophages are a cell population of the innate immune system which are derived from 
the myeloid lineage. They display high plasticity to adapt to their microenvironmental 
signaling through changing their phenotypes (52). Two major phenotypes of macrophages 
have been reported in the tumor microenvironment: M1 macrophages and M2 
macrophages (52). M1 macrophages, or classically activated macrophages, are the pro-
inflammatory phenotype which support tissue defense. M2 macrophages, or alternatively 
activated macrophages, are the anti-inflammatory phenotype which support tumor 
growth and disease progression (51, 53). 
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Macrophage polarization is highly regulated by tumor microenvironmental 
signals. During tumor initiation: inflammatory signals such as IFN-γ and TNF-α stimulate 
macrophages to adapt the M1 phenotype. M1 macrophages secret high levels of 
inflammatory cytokines, such as IL-12 and IL-23, and reactive oxygen and nitrogen species 
which increase macrophages’ killer activity (53, 54). It has been known that M1 
macrophages can recognize and destroy cancer cells and their presence in tumors 
increase the effectiveness of immunotherapy. Increase M1 infiltration is correlated with 
good prognosis in different cancers (55, 56). The cytotoxic activity of M1 macrophages 
toward cancer cells can be through different mechanisms including direct interaction, 
phagocytosis, and cytokines signaling. Studies have shown that macrophages are able to 
selectively kill cancer cells by phagocytosis. Also, macrophage cytotoxicity is mediated by 
the production of TNF-α (57-59). Experimental studies indicated that macrophage 
vaccination of mice can attenuate tumor growth through direct killing of tumor cells by 
M1 macrophages (59).  
However, signaling from cancer cells can promote macrophages polarization to 
M2 phenotype, or tumor-associated macrophages (TAMs). M2 macrophages are induced 
by the secretion of anti-inflammatory signals such as IL-4 and IL-13 (50, 52). In breast 
cancer, studies have shown that increasing M2 infiltration is associated with reduced 
patients’ survival rates (60, 61). Experimental evidence indicates that TAMs play a critical 
role in supporting tumor progression and metastasis through different pathways (51, 53). 
TAMs have a pivotal role in promoting tumor growth. It has been demonstrated that 
TAMs facilitate cancer cell proliferation through secretion of growth factors such as EGF 
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and FGF (62). TAMs also support tumor growth by reducing anti-tumor immunity. TAMs 
secrete high levels of IL-10 which suppress cytotoxic T-cell and natural killer (NK) cell 
activity(63). Moreover, TAMs promote tumor growth via stimulating angiogenesis. It has 
been reported that TAMs produce a wide spectrum of growth factors such as VEGF, PDGF 
and TGF-β to modulate and induce neovascularization (51, 53). It also has been shown 
that TAM-derived MMPs can facilitate angiogenesis, in particular MMP9, which helps 
degrade ECM and further release growth factors (64). In addition to promoting 
angiogenesis, TAM-derived MMPs promote cancer cell migration through the stromal 
tissue which is one of first steps of the metastatic cascade (64). Using breast cancer mouse 
models, it was found that co-injection of M2 macrophages with cancer cells significantly 
increases their metastatic activity (65). Further studies showed that TAMs support cancer 
cell intravasation into the vascular system (66, 67). Furthermore, TAMs can also facilitate 
cancer cell metastasis through ECM remodeling (68). TAMs have also been found to 
support the growth of cancer stem cells, which positively correlated with tumor 
progression and metastasis, through juxtacrine signaling (69). 
Due to the important role of TAMs in tumor progression and metastasis, TAMs are 
considered as strong therapeutic target. Several strategies have been developed over the 
past years to inhibit TAMs activity within the tumor microenvironment including: 
inhibiting TAMs recruitment, blocking TAMs activation signaling, and inducing TAMs re-




1.5. Emodin and Breast Cancer 
 In recent years, an increasing number of research uses natural compounds as a 
source of new drugs. Natural products isolated from Chinese herbs have been found to 
have biological activities (72, 73). Emodin, a trihydroxy-anthraquinone, is the active 
compound of several Chinese herbs. It has been shown that emodin has anti-
inflammatory and anti-cancer properties (74). In different experimental disease models, 
emodin treatment was found to attenuate inflammation by targeting the macrophage 
population through different mechanisms (74-76). Emodin reduces the production of 
inflammatory cytokines such as TNF-α, IL-1β, and IL-6 and can also reduce macrophage 
infiltration (76). Moreover, emodin regulates macrophage activation through blocking 
NFκB and MAP kinase signaling (74). It also has been shown that emodin can regulate 
macrophage phagocytosis, migration, and polarization (77).   
Emodin’s role in regulating the macrophage component makes it as a potential 
therapy for cancer. Experimental studies have shown that emodin treatment reduces 
tumor growth in different pre-clinical animal models (74, 78). However, most of these 
studies are focusing on the direct effect of emodin treatment on cancer cells. Different 
mechanisms have been proposed by which emodin represses tumor growth. Studies have 
found that emodin inhibits NFκB, ERK 1/2, p38, JUNK and PI3K/AKT signaling pathways in 
different cell lines (78). Also, emodin induces apoptosis in many cancer cell lines through 
different pathways including caspase dependent and independent pathways (79-81). On 
the other hand, few studies have found that emodin treatment can modulate the tumor 
microenvironment. Emodin was found to inhibit angiogenesis in pancreatic cancer model 
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through reducing NF-κB signaling and its regulation of angiogenesis-associated factors 
VEGF, MMP-2, MMP-9, and eNOS (82). Emodin can also inhibit angiogenesis by 
attenuating endothelial cell proliferation, migration and tube formation through blocking 
VEGF-A receptor-2 (KDR/Flk-1) signaling (83). In addition to its role in angiogenesis, 
emodin has been shown to reduce tumor growth and lung metastases by targeting 
macrophages. Using breast cancer mouse models, emodin attenuates tumor growth by 
inhibiting macrophage infiltration and M2 phenotype polarization in tumors (84). Emodin 
can also reduce lung metastasis through reducing M2 macrophages infiltration into lung 
tissue (85).  
1.6. Breast Cancer Laterality and the Mammary Microenvironment 
 Based on epidemiological studies, breast cancer is a lateralized disease with more 
tumors forming in the left breast (86-91). However, right-sided tumors are more 
aggressive and have earlier metastatic development (88, 90, 91). Moreover, some studies 
indicate that patients with right-sided breast cancer have poorer overall survival rates 
than patients with left-sided breast cancer (91-93). Although these finding indicate left-
right differences in tumor biology, no functional studies exist to identify the causes of 
these left-right difference. In an attempt to overcome this limitation, we will study the 
left-right differences in tumor biology, metastasis, and therapeutic response.    
 Mammary glands develop as paired structures, and it has been known that 
developmental signals are unique for each gland (94, 95). During embryonic 
development, the formation of mammary placodes, which form the ducts, seems to be 
enhanced in the  left side (94). Also, somites which contribute to mammary gland 
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formation, particularly the stromal components, have left-right differences in gene 
expression (96, 97). Moreover, in different developmental stages, it has been 
demonstrated that mammary glands are molecularly lateralized despite their similar 
morphology (92).  A microarray analysis of mouse mammary glands yielded 161 
transcripts that are left-right differentially expressed, including genes known to regulate 
mammary tumorigenesis (92).  Knowing that mammary glands exhibit left-right 
differences at the molecular level allows us the opportunity to test the role of the 
microenvironment in breast cancer laterality by using the same seed. This hypothesis will 
be tested in chapter 3 and 4. 
1.7. Specific Aims and Significance  
 In this study we will investigate the role of the mammary microenvironment in 
promoting left-right differences in breast cancer progression, metastasis, and therapeutic 
response. We developed three specific aims: 1) Determine if the mammary epithelial 
microenvironment has an effect on tumor progression and/ or metastasis when 
compared to the stromal microenvironment. 2) Determine if the mammary 
microenvironment promotes left-right differences in tumor progression and/ or 
metastasis. 3) Determine if left versus right mammary tumors respond differently to 
emodin treatment. 
The mammary microenvironment is composed of two main components: 
epithelium and stroma(18). However, breast cancer mouse models are generated by 
incubating tumor cells into the stromal microenvironment and altogether bypassing the 
epithelial microenvironment. Strong evidence shows that the epithelium is an important 
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component of the mammary microenvironment (46-48, 98). Moreover, human breast 
cancer originates within the epithelial components. Therefore, specific aim one will test 
the hypothesis that the mammary epithelial microenvironment influences tumor 
progression and metastasis when compared to the stromal microenvironment. To test 
this hypothesis, we will generate the mammary tumor within the epithelial 
microenvironment using an intraductal injection of tumor cells. Tumor growth rate, 
tumor histopathology, molecular profile will be examined for the intraductal generated 
tumors and compared to what has been reported for stromal generated tumors of the 
same cancer cells. Chapter 2 will show that adding the epithelial component impacts 
mammary tumor properties. Using an intraductal mouse model will provide more insight 
on overlooked tumor progression and/ or metastatic regulators which may lead to the 
development of new therapeutic strategies.  
Knowing that the normal mammary microenvironment exhibits left-right 
differences at the molecular level (92), specific aim two will investigate if left and right 
mammary microenvironments will support tumorigenesis differently. Epidemiological 
studies show that more aggressive tumor subtypes more often form in the right breast. 
Moreover, patients with right side breast tumors have poorer survival rate (88, 90-92, 
99). These findings suggest left-right differences in tumor biology depend on tumor 
location, which suggests left-right differences in the microenvironmental support to these 
tumors. Therefore, the second specific aim will test the hypothesis that left versus right 
mammary microenvironments differently support tumor progression and metastasis. To 
test this hypothesis, we will inject the same number of the same cancer cells into either 
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left or right mammary glands. Molecular profile, macrophage content and polarization, 
and metastatic activity will be examined for left versus right tumors. These results will 
demonstrate for the first time that the right mammary microenvironment promotes more 
M2 macrophages, resulting in more aggressive tumors with more metastatic activity. 
Understanding the left-right differences in tumor biology is essential to better 
understanding clinical outcomes in breast cancer patients.  
There has been an increasing interest in using natural compounds isolated from 
Chinese herbs as a source of new cancer therapy. Emodin, the active ingredient of several 
Chinese herbs, is known to have anti-cancer activity through targeting cancer cells and 
their microenvironment (72, 80, 82, 83). Emodin’s ability to target tumor 
microenvironment, particularly M2 macrophages, makes it as a potential breast cancer 
therapy. Knowing that the mammary microenvironment promotes left-right differences 
in M2 macrophages polarization, specific aim three will test the hypothesis that left versus 
mammary microenvironments respond differently to emodin treatment. To test this 
hypothesis, mice bearing left versus right tumors will be treated with emodin. 
Macrophage content and polarization, stem cell content, and metastasis will be examined 
for left versus right emodin treated tumors. These results will demonstrate for the first 
time that mammary tumors exhibit left-right differences in therapeutic response. These 
results indicated that tumor side is an important aspect to consider for clinical treatment 
of breast cancer patients.
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Chapter 2 
Role of epithelial microenvironment in mammary tumors progression and 
metastasis 
2.1. Introduction 
Although metastatic breast cancer is the main cause of death in breast cancer 
patients, there is still no treatment available to treat or prevent metastasis. In part, most 
preclinical mouse models used to study tumor progression and metastasis do not fully 
recapitulate human breast cancer conditions (100, 101). One of the reasons for this 
limitation is that the mammary gland contains two distinct microenvironments: the 
epithelium, ductal network, and the stroma, fat pad. Human breast cancer originates 
within the epithelial microenvironment, but breast cancer mouse models are generated 
by delivering tumor cells into the stromal microenvironment using fat pad injection and 
bypassing the other microenvironment, the epithelium (102). Lots of studies have shown 
that the stromal microenvironment plays a major role in regulating tumor progression 
and metastasis (36, 45, 103). However, strong evidence demonstrates that mammary 
epithelial cells are able to regulate cells of non-mammary origin as well as transformed 
cells’ fate such as adult testicular cells, bona fide neural stem cells, MMTV-neu-
transformed cells, and human embryonal carcinoma cells (46-49, 98). Thus, failure to 
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consider effects of the epithelial microenvironment might be a significant omission in 
developing mouse models that recapitulate human breast cancer conditions. 
Some mouse models have been adapted to include the effects of the epithelial 
microenvironment in studying mammary tumor initiation such as ductal carcinoma in situ 
mouse models. In these models, an intraductal injection delivers tumor cells directly into 
the epithelial microenvironment through the teat (104, 105). However, using this 
approach in studying tumor progression and metastasis is still limited. A study 
investigated the effects of the epithelial microenvironment on tumor progression and 
metastasis using a metastatic mouse model. Sflomos et al. showed that when ER+ 
(Estrogen Receptor positive) tumor cells are implanted into the epithelial 
microenvironment, they grow and metastasize differently compared to fat pad 
implantation of the same tumor cells. Furthermore, they showed that different tumor 
behavior is due to different microenvironmental signaling, epithelium versus stroma 
(106).  
Another reason for the limitation in developing breast cancer mouse models is 
that mice have five pairs of mammary glands, and it has been reported that each 
mammary gland is different in its normal development and susceptible to pathogenesis 
(94). Human breasts are located anatomically in the thoracic area while most of the fat 
pad generated tumors are established in the fourth pairs of the mouse mammary glands 
that are located in the inguinal area. Moreover, based on the anterior-posterior 
anatomical location of human breasts, the thoracic glands, the third pair of the mouse 
mammary glands, most closely model human breast anatomical location (94).  
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Furthermore, the signaling pathways during mouse mammary gland development differ 
amongst the five pairs and the signaling of thoracic glands closely model human breast 
development (94). Thus, choosing the “wrong” mammary gland in mouse models may be 
another significant limitation in developing breast cancer mouse models. 
Attempting to overcome these two limitations in breast cancer mouse models, we 
investigated whether adding the epithelial microenvironment and using mouse thoracic 
glands can effect tumor progression and metastasis. In this study, we chose a widely used 
mouse model for triple negative breast cancer, the 4T1 mouse model. In order to 
determine if our approach gives different tumor progression and metastasis compared to 
the currently used mouse models of the same tumor cells, several 4T1 tumor properties 
were measured and compared to what has already been reported for 4T1 fat pad/inguinal 
generated tumors. Here, we show that generating 4T1 tumors within the epithelial 
microenvironment of thoracic glands change histological and molecular features of 4T1 
tumors. Compared with previously reported fat pad 4T1 tumors, the resulting intraductal 
tumors exhibited different properties, including faster growth rate, differences in 
histopathological features, metastatic behavior, and gene expression profile. Taken 
together, our results indicate that the epithelial microenvironment of the thoracic gland 
promotes more aggressive 4T1 tumors compared to what has been reported for the 4T1 





2.2. Material and Methods 
2.2.1. Mice 
All experimental methods were conducted under a protocol approved by the 
Institutional Animal Care and Use Committee IACUC of the University of South Carolina 
according to National Institutes of Health guidelines. Female BALB/c mice (16 weeks old, 
22-25 gram in weight) were purchased from Jackson Laboratory. Mice were housed in the 
University of South Carolina Animal Research Facility.   
2.2.2. 4T1-Luc2-RFP Cell Line 
The parental 4T1-Luc2 cell line was purchased from the American Type Culture 
Collection (ATCC) which originally labeled with luciferase (Luc). Upon purchase this cell 
line, red fluorescence protein (RFP) was inserted into the 4T1-Luc2 cell line using a pWPI-
RFP lentiviral vector. 4T1-Luc2-RFP cells were maintained in RPMI 1640 media 
supplemented with 10% FBS, 100 U/ml penicillin (Sigma-Aldrich St. Louis, MO) and 100 
µg/ml streptomycin (Sigma-Aldrich) at 37C° in a humidified CO2 incubator.  
2.2.3. Intraductal Implantation of 4T1-Luc2-RFP Cells 
Before implantation, 4T1-Luc2-RFP cells were allowed to grow for two days. Cells 
from the second passage were collected, counted, and resuspended in sterile PBS at a 106 
cells/ml concentration.  Mice were anesthetized using isoflurane. 5 µl of cells suspension 
(containing 5000 4T1-Luc2-RFP cells) was injected intraductally into the right thoracic 
mammary glands of the anesthetized mice using a previously described method12, but 
without surgically opening the mouse. Briefly, a Hamilton syringe with a 30-gauge blunt-
ended 0.5-inch needle was used for the intraductal implantation. The mice were 
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anesthetized and placed under a dissecting microscope. The teat of the thoracic gland 
was snipped and the needle was inserted directly into the mammary duct through the 
opening of the teat. 
2.2.4. Monitoring Tumor Growth 
After 4T1-Luc2-RFP intraductal tumors became palpable, tumor volume was 
monitored by: (1) external caliper measurements, tumor volume was measured semi-
weekly using a digital calipers (tumor volume = (length * width2)/ 2).  
(2) Bioluminescence imaging, mice were imaged weekly using IVIS Lumina system 
(PerkinElmer) as previously described(107). Briefly, D-Luciferase (10 µg/gram of body 
weight) was injected intraperitoneally (IP). Images were acquired 10 minutes following 
the D-Luciferase injection. Live imaging software was used to quantify photons emitted 
by the tumor cells.   
2.2.5. Histology and Image Collection 
Trichrome staining of paraffin embedded tissue was used for histological 
examination (local invasiveness, necrosis, collagen deposition and fibrosis) of the primary 
tumors. To study metastasis in distant organs such as lungs, liver, and spleen, standard 
hematoxylin and eosin staining was performed. 25 sections were stained for each organ, 
each set of 5 sections was collected from different levels within the organ. The stained 
sections were examined and photographed using a Nikon Eclipse Ni microscope. 
2.2.6. Immunofluorescence Staining of RFP 
4 µm sections of 4% paraformaldehyde fixed and paraffin embedded tissue were 
used for RFP immunofluorescence staining using the manufacturer’s protocol (Novus 
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Biologicals, USA). Briefly, sections were deparaffinized in xylene and rehydrated through 
graded ethanol series. Antigen retrieval was performed on slides heated in 10mM citrate 
buffer (pH = 6.0) in water bath for 30 min at 95C°. After blocking with 5% donkey serum, 
RFP primary antibody (Novus Biologicals, USA) was added in concentration of (3 µg/ml). 
Slides were incubated for one hour at room temperature (RT) followed by overnight 
incubation at 4C°.  After washing, slides were incubated with secondary antibody (1µg/ml 
- Alexa Fluor 594) for two hours at RT. DAPI staining was added for nuclear labeling 
followed by mounting media and coverslips. Slides were photographed using a Nikon 
Eclipse Ni microscope.    
2.2.7. Isolating Tumor 4T1-Luc2-RFP Cells and RNA Isolation  
4T1-Luc2-RFP cells were isolated from the 4T1-Luc2-RFP intraductal tumors by RFP 
expression. Tumors were harvested at day 24 post tumor cells injection and processed for 
single cell suspension. Briefly, tumor tissue (600-800 mg) were dissociated: first 
mechanically using sterile scalpels into less than 1mm3 pieces and then enzymatically 
using a mix of collagenase IV (4 mg/mL), Hyaluronidase (1 U/mL), and DNase I (20 µg/mL) 
(Sigma-Aldrich St. Louis, MO) in 5mL of serum-free DMEM medium for 1 hour at 37C° 
shaking water bath. After washing from the enzyme mix, pellets were resuspended in 5mL 
RBC lysis buffer for 3 min at room temperature. After washing from the RBC lysis buffer, 
the cell suspension was passed through a 70 µm cell strainer to obtain the single cell 
suspension. RFP positive 4T1 cells were sorted using fluorescence-activated cells sorting 
(FACS). The sorted RFP+ 4T1 cells were collected in tubes contain QIAzol lysis reagent and 
processed for RNA extraction using Qiagen kit.   
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2.2.8. RNA-Seq Analysis 
Three independent RNA preparation from 4T1-Luc2-RFP cultured and intraductal 
tumors’ FACS 4T1-Luc2-RFP cells were used to conduct RNA sequencing analysis. The 
RNA-Seq libraries were created using the TruSeq RNA Sample Prep kit. Libraries were 
sequenced on HiSeq 2500, following the manufacturer’s protocols. The mapping of the 
processed reads was performed by using HISAT with mm10 reference genome; reads 
were counted by using HTSeq (108, 109). Genes showing less than 10 counts on average 
across all samples were removed, resulting in 14,027. The remaining values were 
normalized with TMM normalization method and then transformed with voom 
transformation (110, 111).  
2.2.9. Statistical Analysis 
 For all the experiments, the data was represented as the mean ± standard error 
of the mean (SEM). For RNA-Seq experiment: Limma package was used to examine 
differential expression between the groups of interest, obtained p-value were corrected 
with BH correction for multiple testing and genes exhibiting corrected p-value < 0.05 were 
considered to be significant and were used in further analysis(112, 113). BINGO plugin in 
Cytoscape environment was used to examine Gene Ontology (GO) Biological processes 







2.3.1. The Epithelial Microenvironment Affects 4T1 Tumor Take and Tumor Latency 
Compared to the Stromal Microenvironment 
In order to determine if the differences in epithelial versus stromal 
microenvironments affect 4T1 tumor take and tumor latency, we generated 4T1 tumors 
within the epithelial microenvironment using the intraductal injection and compared our 
results with what has been reported about the 4T1 fat pad generated tumors. The 4T1-
Luc2-RFP cells were injected directly in the epithelial ducts through the teat of the 
thoracic mammary gland of adult female BALB/c mice (Fig. 2.1). After 7-10 day of the 
intraductal injection, 4T1-Luc2-RFP cells give rise to a palpable tumors with 100% primary 
tumor take. This results are different compared to what have been reported for the fat 
pad generated tumors when injected the same number of cells. 4T1 fat pad tumors 
become palpable at earlier time at 3-5 days post injection but with less tumor take of 96% 
(116).  
2.3.2. The Epithelial Microenvironment Effects 4T1 Tumor Growth Rate Compared to 
the Stromal Microenvironment 
Starting at day 11 post tumor cell injection, tumor growth was monitored over the 
experimental time using two standard methods: First, the 4T1 cells that we used in this 
study were labeled with luciferase which allowed for in vivo monitoring of tumor growth 
using an in vivo imaging system (IVIS).  The luminescence data of 4T1-Luc2-RFP intraductal 
tumors showed an increase in tumor mass over the five weeks of the experimental time 
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(Fig. 2.2 a, b). Second, tumor volume was also monitored semi-weekly using a digital 
caliper which showed that 4T1-Luc2-RFP intraductal tumors reached an average 2 cm3 in 
volume (Fig. 2.2 c) and an average 2 g in weight (Fig. 2.2 d) at five weeks post-injection. 
Though the 4T1 fat pad tumors started their growth earlier than the 4T1 intraductal 
tumors, the fat pad generated tumors have an average of 1 cm3 tumor volume at 40 days 
post injection (84, 85). Our results indicate that the epithelial microenvironment 
moderately increase growth rate of 4T1 tumors compared to what has been reported in 
the literature for fat pad 4T1 tumors.  
2.3.3. The Epithelial Microenvironment Significantly Affects Collagen Deposition and 
Fibrosis in 4T1 Tumors Compared to the Stromal Microenvironment 
Upon the experimental end point, we examined the histopathology of the 4T1-
Luc2-RFP intraductal tumors to determine if including the epithelial microenvironment 
generates different pathological features compared to what has been reported for the fat 
pad 4T1 tumors. Several histopathological features were examined for 4T1-Luc2-RFP 
intraductal tumor sections stained with trichrome staining, including local muscle 
invasion (Fig. 2.3 a), collagen deposition and fibrosis (Fig. 2.3 b), and immune cell 
infiltration (Fig. 2. 3 c). Based on the literature, all of the above histopathological features 
can be seen in the fat pad 4T1 tumors except for collagen deposition and fibrosis which 




2.3.4. The Epithelial Microenvironment Significantly Affects 4T1 Metastatic Behavior 
Compared to the Stromal Microenvironment 
Based on the fat pad generated tumors of 4T1-Luc2 variant that we used in this 
study, 4T1-Luc2 cells have not reported to metastasize outside of the lung (84, 85). To 
determine if including the epithelial microenvironment when generating 4T1-Luc2-RFP 
tumors affects their metastatic behavior (including tropism and metastatic burden) when 
compared to fat pad generated tumors, we examined several organs such as lungs, liver, 
spleen, brain and bone for the presence of metastatic lesions. Metastatic lesions were 
only found in the lung (Fig. 2.4 a) which matches to what has been reported for the 4T1-
Luc2 variant used in fat pad generated tumors (84, 85). Although no metastatic lesions 
were found in other organs, the histopathology of the spleen and the liver revealed 
extensive extramedullary hematopoiesis by week five post tumor cell injection (Fig. 2.4 c, 
d). Our data indicated that incubating 4T1-Luc2-RFP cells within the epithelial 
microenvironment does not change the tropism of the 4T1-Luc2-RFP cells.  
To assess the metastatic burden of 4T1-Luc2-RFP intraductal generated tumors, 
we examined the lung sections for metastatic lesions after hematoxylin and eosin 
staining. The histopathological examination showed that the number of mice with macro-
metastases increased from week three to week five (87% of the mice at week three, 100% 
at week five) (Fig 2.4 b). Also, the number of the lung lesions increased from an average 
of 2 macro-metastases at week three to an average of 4 macro-metastases at week five 
(n=8 at three weeks time point and n=6 at five weeks time point) (Fig. 2.4 b). Comparing 
to what has been known for fat pad 4T1 tumor metastasis, our results indicate a 
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significant increase in metastatic activity of 4T1-Luc2-RFP cells after the intraductal 
implantation, particularly at three weeks time point. The percentage of mice with lung 
macro-metastases is 0 % at three weeks and 83 % at five weeks post the fat pad 
implantation (116, 120), while we found that the percentage of mice with lung macro-
metastasis is 87 % at week three and 100% at week five post the intraductal implantation. 
2.3.5. The Epithelial Microenvironment Affects the Fluorescence Expression of 4T1 Cells 
Similarly to the Stromal Microenvironment 
In order to assess the molecular change in 4T1 cells after the intraductal 
implantation, we used RFP tagged 4T1 cells to generate the intraductal tumors. First, we 
examined if the 4T1 cells maintain their RFP expression after intraductal implantation by 
staining 4T1 intraductal tumor sections with anti-RFP antibody. Our results show that 25-
30% of the cells in the 4T1 intraductal tumor section are RFP positive cells (Fig. 2.5). This 
data shows that 4T1-Luc2-RFP cells maintain their fluorescence expression after the 
intraductal implantation. This is similar to previously published studies which show that 
fluorescently labeled 4T1 cells, 4T1-GFP and 4T1-RFP, maintain their fluorescence 
expression after the fat pad implantation (116, 121, 122).  
2.3.6. The Epithelial Microenvironment Significantly Affects 4T1 Gene Expression and 
Pathway Analysis Compared to the Stromal Microenvironment 
To determine molecular changes within 4T1 cells after implantation in the 
epithelial microenvironment, we isolated RFP tagged 4T1 cells from the intraductal 
tumors using fluorescence activated cell sorting (FACS). Then, we conducted RNA 
sequencing for the isolated 4T1-Luc2-RFP cells and compared them to non-injected 4T1-
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Luc2-RFP cells. The gene expression profiling revealed 6,374 genes that are differentially 
expressed in the isolated 4T1-Luc2-RFP cells from the intraductal tumors compared to 
non-injected 4T1-Luc2-RFP cells, as shown in the heat map (Fig. 2.6 a). Our results for the 
differential gene expression are significantly different from what has been reported for 
the molecular analysis of 4T1 cells isolated from fat pad generated tumors. Only 395 
genes are differentially expressed in the fat pad isolated 4T1 cells compared to non-
injected 4T1 cells (123), and there are only two genes that are common between 4T1 cells 
isolated from intraductal versus fat pad tumors (Fig. 2.6 b).  
We next subjected the upregulated genes to Gene Ontology analysis, focusing on 
Biological Processes component, which showed significantly affected processes 
associated with the intraductal implantation of the 4T1-Luc2-RFP cells (Fig. 2.6 c). When 
compared our result to the pathways that affected by the fat pad implantation, we found 
that many of these pathways have not been reported to be affected by the fat pad 
implantation of the 4T1 cells. Immune processes was the pathway most affected by 
intraductal implantation of the 4T1 cells. Of these pathways are known to regulate tumor 
progression through modulating TAMs activation such as IL-10, IL-4, and IL-6 signaling 
pathways (124, 125). Other immune processes reported in the intraductal effected 
pathways are reported to regulate tumor immune microenvironment such as IFN gamma 
and toll-like receptor (126, 127). Moreover, some pathways affected by intraductal 
implantation are not reported to be effected by fat pad implantation, such as 
angiogenesis, wnt signaling, JAK-STAT signaling, and Ras signaling, which are known to 
directly support tumor progression and metastasis. 
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2.4. Discussion 
 Our results demonstrate that the epithelial microenvironment differentially alters 
4T1-Luc2-RFP tumor properties, such as growth rate, tumor histopathology, metastatic 
properties, and molecular profiles when compared to what has been reported in the 
literature for 4T1 fat pad generated tumors. Our results also indicate that many of the 
intraductal tumor properties are associated with more aggressive tumors. Collagen 
deposition and fibrosis associated with 4T1 intraductal tumor histopathology has not 
been reported for 4T1 fat pad tumors and is consistent with more aggressive tumors (68, 
103, 128). Thus, using the intraductal mouse model offers opportunity to study and follow 
these important histopathological changes throughout tumor progression and 
metastasis.    
With the metastatic properties of 4T1 intraductal tumors, our data shows that the 
epithelial microenvironment promotes a higher percent and earlier lung metastases 
compared to what has been reported for 4T1 fat pad generated tumors. Studies have 
shown that using fat pad implantation of 4T1 cells requires at least 40,000 cells in order 
to get 100% lung metastasis (107, 116, 129, 130). However, our results show that 
intraductal implantation of a small number of tumor cells (5000 4T1-Luc2-RFP cells) can 
achieve 100% lung metastasis by five weeks post injection. Moreover, our results show 
that lung macro-metastasis presents as early as three weeks post intraductal injection 
while it needs five weeks post fat pad injection to find lung macro-metastases (116). 
Our data also shows that the epithelial microenvironment alters 4T1-Luc2-RFP 
gene expression profile when compared to non-injected 4T1-Luc2-RFP cells. Our data of 
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RNA sequencing analysis of 4T1-Luc2-RFP cells isolated from the intraductal tumors 
versus the cultured 4T1-Luc2-RFP cells yielded 6,374 differentially expressed genes. Other 
studies that used fat pad implantation of 4T1 cells showed that around 395 genes were 
differentially expressed when compared with the parental 4T1 cells (123). Many genes 
associated with the isolated intraductal 4T1-Luc2-RFP cells are consistent with triple 
negative breast cancer progression and metastasis, such as Hoxb, Acta2, Actg2, and Wnt 
(131, 132). These genes have not been reported to be expressed in 4T1 fat pad generated 
tumors. This indicates that the intraductal model of 4T1 cells offers greater opportunities 
to study the metastatic cascade than the fat pad model of 4T1 cells. 
Moreover, some of the genes associated with the isolated intraductal 4T1-Luc2-
RFP are associated with therapeutic response. One such gene, cytotoxic T-lymphocyte 
antigen-4 (Ctla4), is up-regulated (87 fold change) in these cells. Ctla4 is a protein-coding 
gene which transmits an inhibitory signal to immune cells (T-cells in particular) (133). 
Tremelimumab, a monoclonal antibody specifically for Ctla4, has been recently used in 
clinical trials alone or in combination with other anticancer therapeutics to treat patients 
with metastatic breast cancer (134). While studies have found that the anti-Ctla4 alone 
has no effect on 4T1 fat pad tumors (135), our results indicate that the intraductal model 
of 4T1 cells will be a better model to examine anti-Ctla4 therapeutic strategies. Androgen 
receptor AR is another up regulated gene (65 fold change) in 4T1 cells after the intraductal 
implantation and has been used as a therapeutic target in different breast cancer 
subtypes (136). Enzalutamide, targeting AR signaling pathways, has been used in clinical 
trials to treat patients with triple negative breast cancer (ASCO abstract 1003); however, 
29 
4T1 fat pad generated tumors have not been reported to be used to test this therapeutic 
strategy. Our data of Androgen expression indicates that our approach of including the 
epithelial microenvironment make it a good model to test these therapeutic strategies.  
Furthermore, subjecting the upregulated genes to pathway analysis yields over 90 
different pathways that are affected by the intraductal implantation. Immune processes 
were the most effected pathways by the epithelial microenvironment. Some of these 
pathways play a crucial role in regulating tumor progression and metastasis through 
modulating the tumor immune-microenvironment such as IFN-gamma and toll-like 
receptor or regulating TAMs activation such as IL-10, IL-4, IL-6 (124-127). Our results also 
show some pathways that have not been reported to be affected by the fat pad 
implantation such as angiogenesis, wnt signaling, JAK-STAT signaling, and Ras signaling, 
(123). These results indicate that including the epithelial microenvironment in generating 






Figure 2.1: Schematic shows the intraductal injection of 4T1-Luc2-RFP cells into the right 
thoracic mammary glands of BALB/c mice. The needle was inserted directly into the 




Figure 2.2: Growth progression of 4T1 intraductal tumors. (A) Mice were imaged on a 
weekly basis by IVIS starting with second week post-injection to monitor tumor growth as 
shown in a representative mouse. (B) Photon flux per second (ph/sec) was measured 
using IVIS to monitor tumor growth (n=6). (C)Tumor volume was also monitored semi-





Figure 2.3:  4T1 tumor histopathology. Trichrome staining of a 4T1-Luc2-RFP primary 
tumor section illustrating different pathological features including neoplastic muscle 
invasion (M=muscle) (T= tumor) (A), fibrosis and collagen deposition (B), and necrosis 




Figure 2.4: Metastases to lungs and increased hematopoiesis in liver and spleen. 
Hematoxylin and eosin staining of: (A) a lung section showing macro-metastases in the 
lung. (B) The percentage of mice with lung macro-metastasis and the number of macro-
metastasis per lung at two different time points (3 and 5 weeks). (C) A liver section 
showing islands of extramedullary hematopoiesis, and (D) a spleen section with extensive 
extramedullary hematopoiesis as evidenced by the presence of megakaryocytes (arrow 




Figure 2.5: RFP expression in 4T1-Luc2-RFP cells.  Immunofluorescence staining of a 4T1 
primary tumor section shows (A) the percentage of RFP positive cells, and (B) the RFP 





Figure 2.6: Distinct gene expression profiling associated with the intraductal 
implantation of 4T1-Luc2-RFP. (A) A heatmap displaying 6,375 genes that differentially 
expressed after the intraductal incubation of 4T1-Luc2-RFP compared to non-injected 
4T1-Luc2-RFP. (B) Identification of differentially expressed genes (DE) in 4T1-Luc2-RFP 
post-intraductal incubation compared to Tabaries et. al. data of differentially expressed 
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genes in 4T1 cells post-fat pad incubation (Venn diagrams). (C) Pathway analysis of 
differentially expressed genes in 4T1-Luc2-RFP post-intraductal incubation.
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Chapter 3 
Role of Mammary Microenvironment in Promoting Left-Right Differences 
in Tumor Progression and Metastasis 
3.1. Introduction 
Although breast cancer continues to be the most common cancer diagnosis for 
women worldwide, the main cause of breast cancer related death is metastasis (137). To 
address the mechanisms underlying metastatic processes, several investigators proposed 
different hypotheses. The seed and soil hypothesis proposed by Stephen Paget 1989 is 
the most common hypothesis to explain the factors regulating cancer metastasis (5).  
Using this hypothesis, a growing number of studies highlighted the importance of the 
seed (cancer cells) as well as the soil (tissue microenvironment) of metastatic sites in 
regulating metastatic processes (36, 138). However, the effect of the primary tumor 
microenvironment in regulating metastasis has been ignored. Therefore, studying the role 
of the mammary microenvironment in regulating breast cancer metastasis will uncover 
unappreciated factors that contribute to metastatic processes. 
Breast cancer originates in mammary glands, particularly within the epithelium. 
When carcinoma occurs, the primary tumor not only contains cancer cells but also 
different cell types that are recruited to the primary tumor location, all of which make up 
the primary tumor microenvironment (139, 140). During tumor progression, cancer cells- 
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recruited cells interactions play a major role in regulating the primary tumor 
microenvironment to support tumor growth and metastasis. In addition to that, normal 
components of the mammary glands are still present within the primary tumors. 
However, the role of the normal components in tumor progression and metastasis has 
not yet been studied. In an attempt to overcome this limitation, this study aimed to 
investigate the role of the mammary microenvironment in tumor progression and 
metastasis. 
 Mammary glands develop as paired structures, and it has been known that 
developmental signals are unique for each gland (94, 95). Moreover, it has been 
demonstrated that despite their morphological symmetry, there are transcriptional 
differences in left versus right mammary glands in mice (92).  A microarray analysis of 
mouse mammary glands yielded 161 transcripts that are left-right differentially 
expressed, including genes known to regulate mammary tumorigenesis and therapeutic 
sensitivity. Knowing that mammary glands exhibit left-right differences at the molecular 
level allows us the opportunity to study the effect of molecularly different mammary 
microenvironments (soils) on metastatic behavior while using the same cancer cells 
(seeds).  
To determine if there are left-right differences in the mammary 
microenvironmental support of tumor progression and /or metastatic behavior, we have 
performed functional studies using the 4T1 TNBC mouse model. Metastatic 4T1-Luc2-RFP 
(luciferase; Red Fluorescent Protein) mammary carcinoma cells were incubated in either 
the left or right mammary glands. Several features of tumor progression and metastasis 
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were monitored over the experimental time and compared between left versus right 
tumor groups. Here we show that despite their equivalent growth rate and end point 
mass, left and right tumors are different in their molecular profile, histopathological 
features, and metastatic behavior. This study presents for the first time the unappreciated 
role for the left versus right mammary microenvironments in the specification of tumor 
progression and metastasis. Moreover, we determine the clinical relevant of our mouse 
data using the publically available breast cancer data bases. Our results show that human 
breast tumor exhibit left-right differences in their genomic profile and our mammary 
tumor mouse signature is linked to human survival rates.   
3.2. Material and Methods 
3.2.1. Mice 
All experimental methods were conducted under a protocol approved by the 
Institutional Animal Care and Use Committee IACUC of the University of South Carolina 
according to National Institute of Health guidelines. Female virgin BALB/c mice (16 weeks 
old, 22-25 gram in weight) were purchased from Jackson Laboratory. Mice were housed 
in the University of South Carolina Animal Research Facility.   
3.2.2. 4T1-Luc2-RFP Cell Line 
The parental 4T1-Luc2 cell line was purchased from American Type Culture 
Collection (ATCC) were originally labeled with luciferase (Luc), and labeled with RFP as 
described in chapter 2. 4T1-Luc2-RFP cells were maintained in RPMI 1640 media 
supplemented with 10% FBS, 100 U/ml penicillin (Sigma-Aldrich St. Louis, MO) and 100 
µg/ml streptomycin (Sigma-Aldrich) at 37C° in a humidified CO2 incubator.  
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3.2.3. Intraductal Implantation of 4T1-Luc2-RFP Cells 
Before implantation, 4T1-Luc2-RFP cells were allowed to grow for two days. Cells 
from the second passage were collected, counted, and resuspended in sterile PBS at a 106 
cells/ml concentration.  Mice were anesthetized using isoflurane. 5 µl of cell suspension 
(containing 5000 4T1-Luc2-RFP cells) was implanted intraductally into the left thoracic 
mammary glands, for the first group, or right thoracic mammary glands, for the second 
group, of anesthetized mice using a previously described method12, but without surgically 
opening the mouse. Briefly, a Hamilton syringe with a 30-gauge blunt-ended 0.5-inch 
needle was used for the intraductal implantation. The mice were anesthetized and placed 
under a dissecting microscope. The teat of the thoracic gland was snipped and the needle 
was inserted directly into the mammary duct through the opening of the teat. 
3.2.4. Monitoring Tumor Growth 
After 4T1-Luc2-RFP intraductal tumors became palpable, tumor volume was 
monitored for each group (left versus right) by: (1) external caliper measurements; tumor 
volume was measured semi-weekly using digital calipers (tumor volume = (length * 
width2)/ 2).  
(2) Bioluminescence imaging; mice were imaged weekly using IVIS Lumina system 
(PerkinElmer) as previously described (107). Briefly, D-Luciferase (10 µg/gram of body 
weight) was injected intraperitoneally (IP). Images were acquired 10 minutes following 
the D-Luciferase injection. Live imaging software was used to quantify photons emitted 
by the tumor cells. 
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3.2.5. Monitoring Body Weight and End Point Tumor Mass 
Body weight of left versus right injected mice groups was monitored weekly using 
a Scout Pro SP202 scale. At the experimental end point, left versus right primary tumors 
were harvested and weighed using an APX-60 (Denver Instrument) scale.  
3.2.6. Tumor Histopathology and Image Collection 
Trichrome staining of paraffin embedded tissue was used for histological 
examination (local invasiveness, encapsulation, collagen deposition and fibrosis) of the 
left versus right primary tumors. The stained sections were examined and photographed 
using a Nikon Eclipse Ni microscope. 
3.2.7. Immunofluorescence Staining of Ki-67 
4 µm sections of 4% paraformaldehyde fixed and paraffin embedded tumors 
tissue were used for Ki-67 immunofluorescence staining using the manufacturer’s 
protocol (Bio-Legend). Briefly, sections were deparaffinized in xylene and rehydrated 
through graded ethanol series. Antigen retrieval was performed on slides heated in 
10mM citrate buffer (pH = 6.0) in water bath for 30 min at 95C°. After blocking with 5% 
goat serum for 30 minutes, Ki-67 (monoclonal rat anti-mouse) primary antibody (Bio-
Legend) was added in concentration of (5 µg/ml). Slides were incubated for one hour at 
room temperature (RT) followed by overnight incubation at 4C°.  After washing, slides 
were incubated with secondary antibody (1µg/ml - Alexa Fluor 488) for two hours at RT. 
DAPI staining was added for nuclear labeling followed by mounting media and coverslips. 
Slides were photographed using a Nikon Eclipse Ni microscope. Five different field of view 
were imaged and analyzed for each tumor sample. The percentage of Ki-67 was calculated 
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for each tumor sample by counting the number of Ki-67 positive cells dividing the number 
of the live cells DAPI positive cells.   
3.2.8. Quantification of Micro-Metastasis of Left versus Right Groups 
Micro-metastases were quantified in different organs using colony assay as 
described previously (129). Briefly, at five weeks post tumor cell injection, lungs, brain, 
liver, and spleen were harvested and transferred to 6-well plates containing 1 X HBSS 
(Hank’s balanced salt solution- Gibco) to remove any remaining blood. Each organ was 
minced using sterile scalpels into less than 1 mm3 pieces. For lungs and brain, the minced 
tissues were mixed with 2.5 ml collagenase IV/ elastase cocktail (5 mg collagenase IV in 
2.5 ml HBSS and 30 units elastase) for enzyme digestion. The lung samples were incubated 
at 4°C for 75 minutes while the brain samples were incubated at 37°C for 120 minutes. 
For liver and spleen, the minced tissues were mixed with 2.5 ml collagenase type I cocktail 
(5 mg collagenase I in 2.5 ml HBSS) for enzyme digestion and incubated at 37°C for 30 
minutes. 
After completion of the enzyme digestion, samples were filtered through 70 µm 
nylon cell strainers, and the suspension was centrifuged for 5 minutes at 1500 rpm at 
room temperature. After washing the pellets with HBSS, the pellets were resuspended in 
10 ml culture medium (IMDM supplemented with 10 % FBS, 1 X antibiotic-antimycotic- 
Life Technology, and 60 µM 6-thioguanine- sigma) and plated onto 10 cm tissue culture 
dishes and incubated in 37°C tissue culture incubator, 5% CO2 for 11 days.  
To count the metastatic colonies, the culture medium was discarded and the 
colonies were fixed by adding 5 ml methanol to each plate and incubated at RT for 5 min. 
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After rinsing the colonies with 5 ml distilled water, 5 ml of 0.03 % methylene blue solution 
was added to each plate to stain the colonies. After rinsing the colonies with 5 ml distilled 
water, the plates were allowed to dry before counting the colonies.  
3.2.9. Quantification of Macro-Metastasis of Left versus Right Groups 
 To study macro-metastasis in distant organs such as lungs, brain, liver, and spleen 
of left and right tumors groups, standard hematoxylin and eosin staining was performed. 
25 sections were stained for each organ, each set of 5 sections was collected from 
different levels within the organ. The stained sections were examined and photographed 
using a Nikon Eclipse Ni microscope. 
3.2.10. Isolating Tumor 4T1-Luc2-RFP Cells from Left versus Right Tumors and RNA 
Isolation  
4T1-Luc2-RFP cells were isolated from the 4T1 intraductal tumors by RFP 
expression. Left and right tumors were harvested at day 24 post tumor cells injection and 
processed for single cell suspension as described in chapter 2 section (2.2.7). RFP positive 
4T1 cells were sorted using fluorescence-activated cells sorting (FACS). The sorted RFP+ 
4T1 cells from left or right tumors were collected in tubes containing Qiazol lysis reagent 
and processed for RNA extraction using Qiagen mini kit following the manufacture’s 
protocol.   
3.2.11. RNA-Seq Analysis 
Three independent RNA preparation from 4T1-Luc2-RFP cultured and FACS 4T1-
Luc2-RFP cells were used to conduct RNA sequencing analysis. The RNA-Seq libraries were 
created using the TruSeq RNA Sample Prep kit. Libraries were sequenced on HiSeq 2500, 
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following the manufacturer’s protocols. The mapping of the processed reads was 
performed by using HISAT with mm10 reference genome; reads were counted by using 
HTSeq (108, 109). Genes showing less than 10 counts on average across all samples were 
removed, resulting in 14,027. The remaining values were normalized with TMM 
normalization method and then transformed with voom transformation (110, 111).  
3.2.12. Isolating Tumor-Associated Macrophages from Left versus Right Tumors 
Tumors were harvested at day 24 post tumor cells injection and processed for 
single cell suspension. Briefly, tumor tissue (600-800 mg) were dissociated: first 
mechanically using sterile scalpels into less than 1mm3 pieces and then enzymatically 
using a mix of collagenase IV (4 mg/mL), Hyaluronidase (1 U/mL), and DNase I (20 µg/mL) 
(Sigma-Aldrich St. Louis, MO) in 5 mL of serum-free RPMI medium for 1 hour at 37 °C 
shaking water bath. After washing from the enzyme mix, pellets were resuspended in 5 
mL RBC lysis buffer for 3 min at room temperature. Then, the cell suspension was passed 
through a 70 µm cell strainer to obtain the single cell suspension. Cells then were counted 
and stained with F4/80 anti-body (FITCI- Bio Legend) and incubated at 4°C for 45 min. 
After washing, the F4/80+ cells were then isolated using EasySepTM Mouse FITCI Positive 
Selection Kit (Stem Cell Technologies, Vancouver, BC) as previously described (141).  
3.2.13. Quantitative Real Time PCR (Qpcr) 
 The isolated macrophages from left versus 4T1 tumors were lysed with Qiazol and 
RNA was extracted using Qiagen mini kit following the manufacture’s protocol. Then, 
cDNA was made from 1 µg of RNA using iScript cDNA Synthesis Kit (Bio-Rad Life Science, 
Hercules, CA).  
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SYBR Green-based RT-PCR was preformed to determine left versus right tumor-
associated macrophage polarization using the primers listed in table 3.1. Real-time PCR 
miner was used to calculate CT value (142). Fold changes were determined by delta-delta 
CT relative to GAPDH mRNA. Then data was normalized to the left group.  
3.2.14. Copy Number Alteration and Mutated Genes 
We used the genomic analysis of Copy Number Alteration (CNA) and mutated 
genes that are publically available in cBioPortal (http://www.cbioportal.org/) to test if 
human breast tumors exhibit left-right differences in genomic profiles (143). We used two 
databases in this analysis: (1) the Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) which has a cohort of 2,510 breast cancer patients. (2)  The 
Cancer Genome Atlas (TCGA) which has a cohort of 1,098 breast cancer patients. First, we 
were able to use the annotation in the clinical data to separate 203 (METABRC) and 95 
(TCGA) triple negative breast cancer patients (TNBC) based on their receptors status (ER-
, RP-, and HER2-). TNBC patients were further separated into left and right groups based 
on the sidedness annotation. Genes presented in less than 10% of TNBC tumors were 
excluded. The frequency of Genes CNA and mutated genes were compared in left versus 
right TNBC tumors for significant differences. 
3.2.15. Mouse to Human Comparative Genomic Analysis: 
We used a large cohort of breast cancer patients from The Cancer Genome Atlas 
(TCGA) database (n=982) (https://cancergenome.nih.gov/) to test the genes differentially 
expressed between left and right mouse mammary tumors (tables 3.2, 3.3) are also 
regulated in human breast tumors. The differentially expressed genes were used to 
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perform Gene Set Enrichment Analysis (GSEA) (144, 145) to examine whether they are 
significantly enriched in left versus right human breast tumors. 
A large cohort of 1,593 breast cancer patients from multiple studies available 
through the Gene Expression Omnibus GEO database 
(http://www.ncbi.nlm.nih.gov/geo/) was used to test the association between molecular 
left-right differences of mouse mammary tumors and patient survival. The compilation of 
the cohort is described by Dvorkin-Gheva and Hassell (146). Since we are using triple 
negative breast cancer cell line (4T1-Luc2-RFP) in mouse study, we used triple negative 
breast cancer TNBC patients. The Status of ER, PR, and HER2 receptors was determined 
by using predictive signatures(147). We used the disease-free survival as the clinical end 
point in our study; however, when disease-free survival was not available, we 
alternatively used overall survival as the clinical end point. The expression values for each 
gene were standardized so the mean was set to 0 and the standard deviation was set to 
1. Signature scores were calculated for each patients as descried previously (148, 149), 
where positive scores were considered to indicate that a tumor had ‘right-sided’ gene 
expression and negative scores were considered to indicate that a tumor had ‘left-sided’ 
gene expression. 
3.2.16. Statistical Analysis 
 For all the experiments, the data was represented as the mean ± standard error 
of the mean (SEM). To determine the significant differences between left versus right 
tumor groups, we used two-tailed Student’s t-test using GraphPad Prism software. We 
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also used two-tailed proportion tests when comparing the percentages between left and 
right groups. 
 For RNA-Seq analysis, Limma package was used to examine differential expression 
between the groups of interest, obtained p-value were corrected with BH correction for 
multiple testing and genes exhibiting corrected p-value < 0.05 were considered to be 
significant and were used in further analysis (112, 113). BINGO plugin in Cytoscape 
environment was used to examine Gene Ontology (GO) Biological processes (114, 115). 
Hierarchical clustering was performed by using gplots package (https://cran.r-
project.org/web/packages/gplots/index.html). 
 For the survival analysis we used Log-rank available in GraphPad Prism test to 
determine the significant differences between left-sided and right-sided groups(150).   
3.3. Results 
3.3.1. Left versus Right Mammary microenvironments Promote Equivalent Tumor 
Growth but Differentially Affect Mice Body Weight 
In order to determine if left versus right microenvironments effect 4T1 tumor take 
and tumor growth rate differently, we generated 4T1-Luc2-RFP tumors in either the left 
or the right mammary epithelial microenvironment of the thoracic glands. Using an 
intraductal injection (Fig. 3.1 a), we injected the same number of 4T1-Luc2-RFP cells from 
the same passage at the same day and time into either the left or the right thoracic 
mammary glands of adult female BALB/c mice. After 7-10 days past intraductal injection, 
4T1-Luc2-RFP cells give rise to palpable tumors with 100% primary tumor take for both 
left and right injected groups.  
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After the left and right tumors became palpable, two standard methods were used 
to monitor tumor growth over the experimental time: First, a digital caliper was used to 
measure tumor volume semi-weekly (Fig. 3.1 b) which showed that left versus right 
tumors have similar volume over the experimental time. Second, measuring the luciferase 
activity of 4T1-Luc2-RFP cells allows for in vivo monitoring of tumor growth using an in 
vivo imaging system (IVIS).  The luminescence data of 4T1-Luc2-RFP left versus right 
tumors showed a similar increase in tumor mass over the five weeks of the experimental 
time (Fig. 3.1 c-d). These results indicate that left versus right mammary 
microenvironments similarly support tumor take and tumor growth rate.  
We also monitored mouse body weight over the experimental time. Our results 
show that mice bearing right tumors reduced their body weight over the experimental 
time compared to mice bearing left tumors (Fig. 3.1 e), even though the end point tumor 
mass was equivalent for both groups (Fig. 3.1 f). This data indicates that despite the 
equivalent growth rate and mass, right tumors have a significant effect on mice body 
weight compared to left tumors. This suggests the onset of cachexia in the right tumor 
group which associated with more advanced cancer and metastatic development (151-
153).  
3.3.2. Right Mammary Microenvironment Promotes More Aggressive Histopathological 
Features of 4T1 Tumors 
 To investigate the differences in left versus right 4T1 tumors that cause the 
different effects in body weight, several histopathological features were examined (Fig. 
3.2). Upon the end point, trichrome stained sections from left and right 4T1 tumors were 
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examined for smooth muscle invasion, encapsulation, and collagen deposition and 
fibrosis. Our results show that smooth muscle invasion presents in right side tumors with 
significantly more frequency (83%) compared to 33% in left side tumors (Fig. 3.3 A-1, B-
1). The results also show that there were no significant differences in the presence of 
encapsulation in left versus right tumors (Fig. 3.3 A-2, B-2). Moreover, the 
histopathological analysis shows that 100% of right side tumors show collagen deposition 
and fibrosis compared to only 17% of left side tumors (Fig. 3.3 A-3, B-3). Higher frequency 
of muscle invasion and collagen deposition and fibrosis are known to be associated with 
more aggressive cancers (68, 103, 154). These results indicate that the right mammary 
microenvironment promotes more aggressive tumors compared to the left mammary 
microenvironment.       
3.3.3. Right Mammary Tumors are More Proliferative than Left Tumors 
 For further investigation about the histopathological differences, we examined 
the proliferation rates of left versus right tumors using Ki-67 expression. The percentage 
of Ki-67 positive cells were compared for left versus right tumors. Our results show that 
right tumors demonstrate significantly higher level of Ki-67 expression compared to left 
tumors (Fig. 3.3). This data indicates more proliferative activity of right tumors which 
matches what has been reported about Ki-67 expression in human breast cancer (155).  
3.3.4. Right Mammary microenvironment Promotes More Metastasis Compared to Left 
Mammary Microenvironment 
 To assess the metastatic behavior of left versus right 4T1-Luc2-RFP tumors, we 
examined the lungs of left versus right tumor groups for the presence of lung micro and 
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macro metastasis. We used the colony assay to determine lung micro-metastasis in left 
versus right groups (n=7 per group). Our results show that 100% of the mice with right 
side tumors have micro-metastases compared to 57% in the left tumor group (Fig 3.4 a). 
Then we examined hematoxylin and eosin stained lung sections to determine the 
presence of lung macro-metastasis in left versus right tumor groups (n=15 per group). Our 
data shows that 87% of mice with right tumors have lung macro-metastasis while only 
40% of the left tumor group have macro-metastasis at three weeks post tumor cells 
injection (Fig. 3.4 b). Moreover, the number of lung macro-metastasis was significantly 
higher in the right tumor group compared to the left tumor group (Fig. 3.4 c-e). 
 Our results also show that at five weeks post tumor cells injection, there were no 
significant differences in the percentage of mice with macro-metastasis in left versus right 
tumors group (Fig. 3.4 f).  However, the number of lung lesions was significantly higher in 
the right tumor group compared to the left tumor group (Fig. 3.4 g). 
 Altogether, the metastasis data (micro, macro-metastasis, and the number of 
lesions) shows that the right tumors are significantly more metastatic than the left 
tumors. This indicates that right mammary microenvironment promotes more aggressive 
4T1-Luc2-RFP tumors, consistent with more aggressive tumor progression in right-side 
breast cancer patients (90, 91).  
3.3.5. Left versus Right Mammary microenvironments Promote Differences in Tumor 
Cells Transcriptome   
To determine the mechanisms of right tumors being more aggressive than the left 
tumors, we conducted a comparative analysis of global gene expression changes in cancer 
51 
cells isolated from left versus right tumors. To do that, we isolated 4T1-Luc2-RFP cells 
from left versus right tumors using fluorescence activated cells sorting (FACS), taking 
advantage of the RFP expression, as shown in the schematic (Fig. 3.5 a). Then, we 
conducted RNA sequencing for the isolated 4T1-Luc2-RFP cells and compared the left 
versus right gene expression profiles. RNA-Seq analysis yielded of 177 differentially 
expressed genes (24 left upregulated genes listed in tables 3.2, and 153 right upregulated 
genes listed in table 3.3) in the isolated 4T1-Luc2-RFP cells from left tumors compared to 
right tumors, as shown in the heat map (Fig. 3.5 b). Most of upregulated genes in right 
isolated 4T1-Luc2-RFP cells are associated with more advanced cancer and metastatic 
behavior such as ADAM, COL, HOX genes family. While the upregulated genes in left 
isolated 4T1-Luc2-RFP cells are associated with anti-tumor immune processes. These 
results indicate for the first time that left versus right mammary microenvironments 
(soils) promote differential gene expression of cancer cells with more aggressive genes in 
the right side.   
Then, we subjected the 177 gens to pathway analysis, which showed significantly 
different pathways that affected in left versus right isolated 4T1-Luc2-RFP cells (Fig. 3.5 
c). While the main affected pathway in the left tumors is associated with immune 
processes, the pathways affected on the right tumors are associated with more aggressive 
tumors, including pathways that regulate Wnt signaling and ECM remodeling (68, 131, 
156). This data is consistent with what has been described that the pathways affected by 
right mammary glands are associated with oncogenesis (92). 
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3.3.6. Right Mammary Tumors Promote More M2-Like Macrophages   
 Our previous results indicate that right mammary microenvironment promotes 
more aggressive tumor progression compared to the left mammary microenvironment. 
We hypothesize that tumor-associated macrophages (TAMs) (number and/or phenotype) 
are part of the mechanism to promote more metastasis in right tumors. To determine the 
difference in TAMs content in left versus right tumors, we first quantified the total 
number of TAMs (F4/80 positive cells) in left versus right 4T1-Luc2-RFP tumors. Our 
results show that the total number of TAMs is equivalent in left versus right 4T1-Luc2-RFP 
tumors (Fig. 3.6 a). Then, we examined TAMs phenotype (M1 versus M2) by gene 
expression using RT-qPCR. Our data shows that M2 TAMs genes expression were 
significantly elevated in TAMs isolated from right 4T1-Luc2-RFP tumors compared to 
TAMs isolated from left 4T1-Luc2-RFP tumors (Fig. 3.6 b, c).      
This data suggests that promoting more M2-like macrophages increases the 
metastatic activity of right-side tumors, consistent with what has been reported for the 
role of M2 macrophages in promoting more aggressive and metastatic breast cancer(51, 
52, 157).  
3.3.7. Human Breast Cancer Tumors Exhibit Left-Right Differences in Gene Copy Number 
Alteration and Mutated Genes.   
 To determine if human TNBC tumors exhibit left-right differences in genomic 
profiles, the frequency of genes CNA and mutated genes were compared in left versus 
right TNBC tumors. Our results show that there are significant differences in the 
frequency of genes CNA (amplification) between left and right TNBC tumors (table 3.4). 
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Some of the genes that amplified more frequently in the right TNBC tumors are known to 
regulate tumorigenesis and immunosuppressive such as RSPO2, HOOK, and PRDM1 (158-
160). While genes that amplified more frequently in left TNBC tumors are found to be 
associated with anti-tumor immunity such as KLF6, and CD22 (161, 162). Our results also 
show that significant differences in the frequency of mutated genes in left versus right 
tumors (table 3.5). 
3.3.8. Right mammary tumors’ upregulated genes are associated with poorer breast 
cancer patients’ survival 
  To determine if the left-right differences that we found in mouse mammary 
tumors are clinically relevant, the genes identified in our RNA-Seq analysis (tables 3.2, and 
3.3) were evaluated using the publically available databases TCGA and GEO.  Because the 
TCGA database has available annotation of tumors location, left or right breast, we first 
use TCGA database to evaluate if left and right human breast tumors exhibit biological 
association with left-right mouse mammary tumors. To do that, we analyzed the genes 
differentially expressed between the left and the right mouse tumors  shown in table 3.2 
and table 3.3 respectively using Gene Set Enrichment Analysis GSEA for biological 
association. Out of 177 differentially expressed genes, 150 genes were found to be 
represented in the TCGA dataset. These genes were used for the GSEA analysis. The 
enrichment plot (Fig. 3.7 a) shows the distribution of genes up-regulated in right mouse 
tumors across right and left human tumors. The GSEA results show that genes 
upregulated in mouse mammary tumours originating from the right side are enriched in 
human breast tumours originating from the right side. We also found that the genes up-
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regulated in left mouse tumors did not show significant enrichment in left human tumors. 
These results suggest the biological similarities between mouse right mammary tumors 
and the human right breast tumors. 
 For further investigation for the clinical relevance of the biological association 
between mouse mammary tumors and human breast tumors, the left versus right genes 
identified in our RNA-Seq analysis were evaluated in GEO data sets in which patient 
outcomes is known. We used TNBC patients in this analysis. Because GEO datasets lack 
the sidedness of breast tumor location, we used the left versus right profiles identified in 
the mouse mammary tumors RNA-Seq (tables 3.2, and 3.3) to assign patients into left-
sided (305) or right-sided (58) breast tumors. At 5 years time point, our results show 
significant differences in patient’s outcomes between left-sided and right-sided groups 
(Fig 3.7 b). Our results show that the left versus right profiles identified in the mouse 
mammary tumors RNA-Seq are significantly linked to breast cancer patient survival rates, 
and demonstrate that right-sided gene expression is associated with poorer survival. 
3.4. Discussion 
 Despite their equivalent growth rate and end point mass, our results demonstrate 
for the first time that left and right mammary tumors differ in their progression and 
metastatic behavior. In this study, we incubated the same number of the same cancer 
cells in two molecularly different mammary microenvironments (left versus right) (92). 
Our result showed equivalent growth rates for left versus right tumors. However, the 
body weight of mice bearing right tumors was significantly reduced over the experimental 
time. This data suggests the onset of cachexia which associated with aggressive growth 
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and metastatic potential of right tumors (151-153). To investigate the differences in left 
versus right tumors, we examined the histopathological features of left versus right 
tumors. Right tumors possess more advanced features such as more muscle invasion and 
collagen deposition, and higher proliferative rate (Ki-67 expression) compared to the left 
tumors. This data is consistent with a study showed that right-sided breast cancer have 
higher proliferative rate compared with left breast cancer (155). Our results further 
showed that right tumors are more metastatic, more lung cancer incidence with more 
lung lesions per mouse, consistent with more metastatic development reported for right-
sided breast cancers (90).  
 Our results of RNA-Seq analysis show significantly different expression levels (up-
regulated or down-regulated) of 177 genes in left versus right isolated tumor cells. Most 
of the genes that up-regulated in 4T1 cells isolated from right tumors are associated with 
more aggressive disease progression, such as MMPs, several genes from the COL family, 
some Hox family genes, and Wnt (68, 132, 156, 163). In contrast, genes that upregulated 
in 4T1 cells isolated from left tumors are associated with anti-tumor immunity, such as 
CCL12, CXCL13, and CD226 (164-166). Moreover, the pathway analysis shows significantly 
different pathways that are affected in left versus right tumors. These results 
demonstrate for the first time that left versus right mammary glands alter cancer cells’ 
gene expression differently. Our results also indicate that right mammary 
microenvironment promotes more aggressive tumor cells compared to the left side. 
Moreover, our data of mouse left versus right differential genes were associated with 
different survival rates with right genes linked to poorer survival rates. These results are 
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consistent with the Robichaux et. al. study which showed that genes elevated in right 
normal mammary glands are correlated with more aggressive disease progression and 
poorer patients’ survival rate(92). Furthermore, as part of the mechanism for this, our 
data indicates that the right mammary microenvironment promotes more M2-like 
macrophages which are known to support cancer progression and metastasis (50, 157).  
 Taken together the data presented here is the first to show, using a functional 
study, that left and right mammary microenvironments differentially support tumor 
progression and metastasis. Our findings highlight the importance of laterality as a 
parameter to be considered not only in the perspective of modeling human breast cancer 
but also in clinical analysis of breast cancer patients. This study also has broader 
implications on the importance of investigating laterality in other paired organs during 
cancer progression and metastasis. 
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Table 3.1: RT-qPCR primers 
 
Gene Forward Reverse 
GAPDH CAGCAAGGACACTGAGCAAGA TATGGGGGTCTGGGATGGAAA 
IL-10 GGACAACATACTGCTAACCGAC TGGATCATTTCCGATAAGGCTTG 
Arg-1 TGAACAGGCTGTATTAGCCAACA AGCACCCTCAACCCAAAGTG 
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Table 3.2: Upregulated genes in left FACS isolated 4T1-Luc2-RFP cells.   
 




































Kctd11 1.37 Gata6 2.03 
LOC100504703 1.51 Ror2 2.03 
Kcnb1 1.53 Hmx2 2.03 
Adam12 1.53 Hoxb2 2.03 
Pcdhga10 1.53 Snai2 2.04 
Ndst3 1.54 Ehd3 2.05 
P4ha3 1.55 Sobp 2.05 
Lmo7 1.55 Igfbp3 2.08 
Antxr1 1.55 Pnpla3 2.1 
Col4a2 1.56 Nrep 2.1 
Itgb3 1.57 Mcam 2.11 
Ttc41 1.57 Khdrbs3 2.11 
Cttnbp2 1.57 Gria3 2.12 
Creb3l1 1.59 Fhl1 2.12 
Col7a1 1.59 Jph2 2.13 
Slit2 1.6 Gcnt4 2.13 
Egfl7 1.61 Nkd1 2.14 
Snhg18 1.62 Tnc 2.14 
Col5a1 1.63 Tmem47 2.16 
Bgn 1.66 Col6a3 2.17 
Gpc4 1.67 Klhl30 2.18 
C030037D09Rik 1.67 Usp13 2.18 
Sparc 1.68 Cdkn2b 2.23 
Mecom 1.68 Myl9 2.23 
Oacyl 1.68 Kcnmb1 2.26 
Emx2 1.69 Lama1 2.26 
Ccdc80 1.7 Col15a1 2.27 
Brinp3 1.71 Stra6 2.27 
Cdh2 1.72 Tll1 2.28 
Col12a1 1.72 Syt5 2.29 
Crabp1 1.73 Wnt11 2.32 
Prkd1 1.73 Lrrc15 2.33 
Kcnq3 1.74 Mmp15 2.34 
Col5a2 1.75 Nos3 2.35 
Serp2 1.75 Cldn5 2.37 
Nexn 1.76 Cplx2 2.38 
Cthrc1 1.76 Tmem200a 2.38 
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Lpar4 1.77 Emcn 2.38 
She 1.79 AA413626 2.39 
Fam46b 1.79 Prr9 2.4 
Nid2 1.79 Tagln 2.41 
Prss23 1.8 Hey1 2.41 
Htr2a 1.8 Unc5c 2.42 
Mmrn1 1.81 Heyl 2.42 
Tbx3 1.81 Meox1 2.42 
2810454H06Rik 1.82 Pcsk9 2.42 
Gm1141 1.83 Slc12a3 2.45 
Col6a2 1.84 Erg 2.46 
Mmp9 1.85 Ptprn 2.48 
Gpihbp1 1.85 Abca4 2.56 
Adamts9 1.86 Pcdh12 2.56 
Grem2 1.87 Lrrc55 2.6 
Mxra7 1.88 Slc5a5 2.64 
Cnih2 1.88 Cspg4 2.65 
Ncam1 1.88 Krt42 2.66 
Rbp1 1.89 Col11a1 2.7 
Hs6st2 1.89 Mest 2.83 
Lrch2 1.89 Plet1os 2.87 
Fam198b 1.9 Tmem252 2.87 
Gli2 1.91 Gucy1a2 2.88 
Srpx2 1.91 Hoxb7 2.89 
Chsy3 1.92 Hoxb8 2.97 
Tspan6 1.92 Myh11 3.1 
Fjx1 1.94 Fmod 3.11 
Igfbp7 1.95 St8sia2 3.19 
Akap12 1.96 Abcb4 3.2 
Atp8b1 1.97 Ppbp 3.34 
Clec11a 1.98 Enho 3.41 
Msx1 1.98 Tacr1 3.46 
Kcnip4 1.99 Kcne3 3.51 
Rnf223 1.99 Slc8a3 3.63 
Tmem204 1.99 Clca1 3.71 
Slc3a1 2 Palm2 3.8 
Dmd 2 Sox17 3.86 
Hoxc8 2.01 Clhc1 3.97 
Dysf 2.02 Htr1b 4.19 
Epha3 2.02   
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Table 3.4: Copy Number Alteration CNA of left versus right  
human breast tumors 
 
 
Gene p-value Side 
KLF6 < 0.05 Left 
TERT < 0.01 Left 
SDHA < 0.05 Left 
TSHZ3 < 0.05 Left 
CD22 < 0.05 Left 
CEBPA < 0.05 Left 
KMT2B < 0.05 Left 
AKT3 < 0.05 Left 
SMYD3 < 0.05 Left 
FH < 0.05 Left 
HEY < 0.05 Left 
IL-10 < 0.05 Left 
RSPO2 < 0.05 Right 
RUNX1T1 < 0.05 Right 
NBN < 0.05 Right 
CCND2 < 0.05 Right 
HOOK3 < 0.05 Right 
PRDM1 < 0.01 Right 
 
62 
Table 3.5: Mutated genes of left versus right  
human breast tumors. 
 
 
Mutated Genes p-value Side 
SPTA1 < 0.05 Left 
SYNE1 < 0.05 Left 
F5 < 0.05 Left 
FAT1 < 0.05 Left 
PIK3CA < 0.05 Left 
CREBBP < 0.05 Right 
KMT2D < 0.05 Right 
FLG < 0.05 Right 
FRG1 < 0.05 Right 







Figure 3.1: Left versus right 4T1 tumors. (A) Schematic shows the intraductal 
implantation of 4T1-RFP-Luc2 cells into left (group 1) or right (group 2) thoracic glands of 
adult female BALB/c mice. (B) Tumor volume was monitored every three days using digital 
calipers (n=12). (C) Mice were imaged on a weekly basis by IVIS starting second week post-
injection to monitor tumor growth as shown in a representative mouse. (D) Photon flux 
per second (ph/sec) was measured using IVIS to monitor tumor growth (n=12). (E) Mice 
body weight was monitored on a weekly basis (n=12). (F) 4T1 tumor weight was measured 





Figure 3.2: Left versus right 4T1 tumor histopathology. Trichrome staining of left (A) and 
right (B) 4T1 primary tumor sections (10X) illustrating various histopathological features 
that differ between left and right 4T1 tumors. A representative image shows smooth 
muscle (S.M.) and the frequency of smooth muscle invasion (n=6) in left (A-1) and right 
(B-1) 4T1 tumors. A representative image shows the present of encapsulation (black 
bracket) and its frequency (n=6) in left (A-2) and right (B-2) 4T1 tumors. A representative 
image shows collagen deposition (black arrow) and its frequency (n=6) in left (A-3) and 




Figure 3.3: Ki-67 expression in left versus right 4T1 tumors. (A) Representative images of 
immunofluorescence staining of ki-67 expression in 4T1-Luc2-RFP primary tumor sections 
(arrows head) (B) The percentage of ki-76 expression in left versus right tumors (n=10) 




Figure 3.4: Lung micro and macro metastasis of left versus right 4T1 tumor groups. Upon 
sacrifice at three weeks post injection, number of mice with presence of lung micro-
metastasis using colony assay (A) and with presence of lung macro-metastasis were 
quantified using histological analysis three weeks post injection (B). Representative 
images of lung macro-metastasis of left-tumor bearing (C) and right-tumor bearing (D) 
groups. Number of lung lesions in left-tumor bearing versus right-tumor bearing groups 
at three weeks post injection (E). Number of mice with presence of lung macro-metastasis 
at five weeks post injection (F) and the number of lung lesions at five weeks post injection 





Figure 3.5: Distinct gene expression profiling of left versus right FACS isolated 4T1-Luc2-
RFP. (A) Schematic shows the experimental design to isolated 4T1-RFP+ cells from left 
versus right tumors. (B) A heat map displaying 177 genes that differentially expressed 
after intraductal incubation of 4T1-Luc2-RFP in left versus right microenvironment. (C) 
Pathway analysis of differentially expressed genes in 4T1-Luc2-RFP post-intraductal 




Figure 3.6: Tumor-associated macrophage (TAMs) content of left versus right 4T1 
tumors. (A) Percent of TAMs (F4/80+ cells) in left versus right 4T1 tumors. (B) SYBR Green-
based RT-PCR analysis of IL-10 gene expression in TAMs isolated from left versus right 4T1 
tumors and (C) Arg-1 gene expression in TAMs isolated from left versus right 4T1 tumors 




Figure 3.7: Comparative genomic analysis of mouse L-R tumors’ FACS isolated 4T1 
transcriptome with human breast tumors and the association to patients’ survival rates. 
(A) Gene Set Enrichment Analysis plot shows that the genes up-regulated in the right FACS 
isolated 4T1 mouse tumors are enriched in the right breast human tumors. (B) Survival 




Role of Mammary Microenvironment in Promoting Left-Right Differences 
in Response to Emodin Treatment 
4.1. Introduction 
Despite the significant progress in therapeutic strategies, breast cancer is still the 
second leading cause of cancer-related death in women worldwide (167). This is in part 
because there is still no treatment available to prevent or treat metastatic development, 
considered the main cause of death in breast cancer patients. Metastatic development is 
highly supported by the tumor microenvironment which is made up of many different cell 
types beyond tumor cells. Tumor-associated macrophages (TAMs) are the most common 
immune cells present in the tumor microenvironment. TAMs, particularly those displaying 
the M2 phenotype, promote tumor progression and metastasis through suppressing anti-
tumor immunity, stimulating angiogenesis, supporting cancer stem cells, and enhancing 
tumor cells migration and invasion (41, 50, 168, 169). Our data further showed that TAMs 
phenotypes differ in left versus right mammary tumors’ microenvironments. Due to their 
crucial role in cancer progression and metastasis, TAMs are considered a therapeutic 
target for breast cancer metastasis.  
There is increasing use of natural compounds and their derivatives as a source of 
new therapies. A number of active compounds have been purified from traditional 
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medicine, particularly Chinese traditional medicine, and have been found to have a 
biological activity against disease (72, 170, 171).  Emodin is one of these natural 
derivatives isolated from roots and barks of several Chinese herbs. Emodin has been 
found to have anti-inflammatory properties through targeting macrophage activation (74, 
172).  Its ability to target macrophage activation makes emodin a potential therapy to 
treat breast cancer metastasis.  
Studies have shown that emodin treatment inhibits tumor growth and metastasis 
through targeting macrophages. In orthotopic mouse models, emodin treatment blocks 
macrophage-cancer cell interaction within the tumor microenvironment. Moreover, 
emodin treatment was found to reduce M2 macrophage recruitment to the lung (84, 85). 
In addition to emodin’s ability to target macrophages, emodin has a strong potential to 
suppress the growth of various cancer cell lines, including breast cancer cell lines, through 
modulating apoptosis and proliferative pathways (74, 173-175). Furthermore, in vitro 
studies showed that emodin attenuates tumor growth by targeting cancer cells and 
microenvironmental tumor support, such as angiogenesis (82, 84). Studies have also 
shown that emodin can inhibit cancer stem cell self-renewal through targeting different 
signaling pathways such as Notch-1, β-catenin, and STAT3 (176, 177).   
Taking together TAMs’ role in developing breast cancer metastasis, emodin’s 
ability to target TAMs activation and our own results of left-right differences in 
metastasis, we investigated if emodin treatment differentially affects left versus right 
mammary tumor metastasis. Our data showed that emodin significantly reduces the 
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metastasis of right tumors through reducing TAMs content, M2-TAMs phenotype, and 
cancer stem-like cells. In left tumor metastasis, emodin treatment had no effect.  
4.2. Material and Methods 
4.2.1. Tumor Model 
 Female BALB/c mice (16 weeks old) were purchased from Jackson Laboratory (Bar 
Harbor, Maine). Mice were housed in the University of South Carolina Animal Research 
Facility and all experiments were approved by the Institutional Animal Care and Use 
Committee IACUC of the University of South Carolina according to National Institute of 
Health guidelines. 4T1-Luc2-RFP cells (5000 cells/5 µl PBS) were injected intraductally, as 
described in chapter 3, into either the left or right thoracic mammary glands.  
4.2.2. Emodin Treatment 
 Tumor volume was monitored as soon as the tumors become palpable using 
digital calipers every three days (tumor volume = (length * width2)/ 2). When tumors 
become 200 mm3 in volume in average (day 14 post tumor cell injection), emodin 
(40mg/kg) or vehicle (2% DMSO) was injected intraperitoneally in 1 mL PBS once daily 
until mice were sacrificed at day 24 post tumor cell injection.  
4.2.3. Quantify Lung Metastasis  
 In order to quantify lung metastasis incidence and metastasis burden, lungs were 
collected from mice sacrificed at day 24. Standard hematoxylin and eosin staining was 
performed on lung sections. 25 lung sections per mouse were examined for the presence 
of lung lesions. Lung metastasis incidence was determined by the number of mice with 
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the presence of lung lesions in each group. The number of lung lesions per mouse was 
used to calculate the metastasis burden.  
4.2.4. Quantify Tumor-Associated Macrophages Using Flow Cytometric Analysis 
 4T1 tumors were collected at day 24 post tumor cell injection from the four groups 
(left DMSO, left emodin, right DMSO, and right emodin) and processed to obtain a single 
cell suspension as described previously (141). Briefly, using sterile scalpels, tumors were 
cut into less than 1mm3 pieces and then dissociated enzymatically using a mix of 
collagenase IV (4 mg/mL), Hyaluronidase (1 U/mL), and DNase I (20 µg/mL) (Sigma-Aldrich 
St. Louis, MO) in 5 mL of serum-free RPMI medium for 1 hour at 37 °C shaking water bath. 
After washing from the enzyme mix, pellets were resuspended in 5 mL RBC lysis buffer 
for 3 min at room temperature. Then, the cell suspension was passed through a 70 µm 
cell strainer to obtain the single cell suspension and resuspended in staining buffer (PBS 
containing 2% FBS). Cells were then counted and stained with anti-CD45 PE-CY7 and anti-
F4/80 FITCI (Bio Legend) in PBS containing 2% FBS and incubated at 4°C for 45 min. Then, 
the samples were washed twice with the staining buffer and analyzed by flow cytometry 
using a BD FACS flow cytometer and CXP software version 2.2 (BD Biosciences, San Jose, 
CA). Data was collected for 30,000 live events per sample.    
4.2.5. Isolating Tumor Associated Macrophages 
 Tumor-associated macrophages were isolated from 4T1 tumors at day 24 post 
tumor cells injection using EasySepTM Mouse FITCI Positive Selection Kit (Stem Cell 
Technologies, Vancouver, BC) as previously described (141). Briefly, tumors were cut into 
small pieces (1mm3) and digested using a mix of collagenase IV (4 mg/mL), Hyaluronidase 
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(1 U/mL), and DNase I (20 µg/mL) (Sigma-Aldrich St. Louis, MO) in 5 mL of serum-free 
RPMI medium for 1 hour at 37 °C shaking water bath. After washing from the enzyme mix, 
pellets were resuspended in 5 mL RBC lysis buffer for 3 min at room temperature. Then, 
the cell suspension was passed through a 70 µm cell strainer to obtain the single cell 
suspension and resuspended in PBS containing 2% FBS. For cell isolation, 1x107- 1x108 
cells were incubated with 20µL FITCI conjugated anti-F4/80 (Bio Legend). The isolated 
tumor-associated macrophages were directly resuspended in Qiazol and used for RT-PCR 
analysis.   
4.2.6. Quantitative Real Time PCR (qPCR)   
 The isolated macrophages from left versus right DMSO and emodin treated 4T1 
tumors were lysed with Qiazol and RNA was extracted using Qiagen mini kit following the 
manufacturer’s protocol. Then, cDNA was made from 1 µg of RNA using iScript cDNA 
Synthesis Kit (Bio-Rad Life Science, Hercules, CA). 
SYBR Green-based RT-PCR was preformed to determine the effect of emodin 
treatment on left versus right tumor-associated macrophage polarization using the 
primers listed in Table 1, Chapter 3. Real-time PCR miner was used to calculate CT value 
(142). Fold changes were determined by delta-delta CT relative to GAPDH mRNA.  Then 
data was normalized to the left group.  
4.2.7. Tumor-Sphere Culture for Left versus Right Tumors  
Left versus right DMSO and emodin treated tumors were harvested at 24 days 
post tumor cell injection. Tumors were mechanically dissociated into less than 1mm3 
pieces using sterile scalpels, then enzymatically dissociated in Leibovitz’s L-15 medium 
76 
without phenol red (Invitrogen), 1.5 mg/ml trypsin (Invitrogen), and 3 mg/ml collagenase 
I (Invitrogen) at 37°C for 60 min. Samples were then processed to single cell suspension 
as  described previously (178).   
Cells were then counted and plated on ultra-low-adherence 96 plates (Corning) at 
300 cells/well in 300 µL tumor-sphere medium (serum-free and phenol red free DMEM 
media (Gibco) supplemented with 1X B-27 (Gibco), 20 ng/ml basic fibroblast growth factor 
(bFGF, Invitrogen), and 20 ng/ml Epidermal growth factor EGF (Invitrogen). Primary 
tumor-spheres were counted and imaged 10 days after plating. Sphere forming efficiency 
(SFE) was calculated by dividing the number of the spheres by the number of plated cells 
per well multiplied by 100. Primary tumor-spheres then were collected and dissociated 
into single cell suspension and re-suspended in new tumor-sphere medium and plated on 
new ultra-low-adherence 96 plates. Secondary tumor-spheres were counted 10 days after 
plating and self-renewal was calculated by dividing the number of secondary spheres on 
the number of the primary spheres in each well and multiplied by 100%, as described 
previously (179).  
4.2.8. Statistical Analysis 
 For all the experiments, the data was represented as the mean ± standard error 
of the mean (SEM). One-way ANOVA followed by Tukey multiple comparison test were 
used to determine the significant differences among the four groups (left DMSO, left 
emodin, right DMSO, and right emodin). All statistical analyses were performed using 





4.3.1. Emodin Reduces Lung Metastasis in Mice Bearing Right-Side 4T1 Tumors 
 To investigate whether left and right mammary tumor microenvironments have a 
different response to emodin treatment, which is known to reduce breast cancer lung 
metastasis (85, 173), we quantified lung metastasis incidence and burden in left versus 
right emodin treated tumors compared to the control. We first generated 4T1 tumors 
intraductally into either left or right thoracic glands (26 mice per group). After tumors 
became palpable, tumor growth was monitored every three days and when tumor 
volume reached 200 mm3 in average (day 14 post tumor cell injection), left and right 
tumor bearing mice were randomly divided further into four groups (left control, left 
emodin, right control, and right emodin) with 13 mice in each group. Emodin (40 mg/kg) 
or control (2% DMSO) was injected intraperitoneally in 1 mL PBS once daily until mice 
were sacrificed at day 24 post tumor cell injection. Then, hematoxylin and eosin stained 
lung sections (25 lung sections per mouse) were examined for the presence and the 
number of lung lesions in the four groups (left control, left emodin, right control, and right 
emodin).    
 To assess if emodin treatment differentially reduces lung metastasis incidence in 
left versus right groups, the number of mice with the presence of lung lesions was 
quantified in left versus right emodin treated groups compared to the controls. 
Interestingly, our results showed that emodin treatment significantly reduces lung 
metastasis incidence in mice bearing right tumors to 46% compared to control group 92% 
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with lung metastasis. Our results also show that emodin treatment has no effect on lung 
metastasis incidence of mice bearing left tumors 46% compared to control group 42% 
with lung metastasis (Fig. 4.1 a).   
 We also examined if emodin treatment differentially reduces the metastatic 
burden in left versus right tumor bearing mice compared to the controls by quantified the 
number of lung lesions per mouse in all the four groups (left control, left emodin, right 
control, and right emodin). Our results show that in addition to the baseline significant 
left-right differences in control groups, emodin treatment significantly reduces the 
number of lung lesions in mice bearing right tumors when compared to the right control 
group. Emodin treatment has no significant effect on the number of lung lesions in mice 
bearing left tumors when compared to the left control group (Fig. 4.1 b). Our data also 
showed that emodin treatment does not affect tumor growth (Fig. 4.1 c) and tumor end 
point mass (Fig. 4.1 d) in left and right tumors bearing mice compared to the control 
groups. Emodin treatment has been reported to reduce breast cancer lung metastasis in 
different mouse models (85). However, this is the first study to investigate the left-right 
differences in response to emodin treatment. 
 Our results indicate that emodin treatment was able to reduce lung metastasis 
incidence and burden in right tumor bearing mice but not in left tumor bearing mice. Also, 
our results show that reducing metastasis is not a result of inhibiting the primary tumor 
growth or tumor end point mass. This indicates that emodin has the ability to reduce right 




4.3.2. Emodin Treatment Alters Tumors-Associated Macrophages Content in Right 4T1 
Tumors 
 Our results, in chapter 3, indicate that the right mammary microenvironment 
promotes more M2 TAMs which then support more metastatic behavior for right 4T1 
tumors compared to left 4T1 tumors. We hypothesize that TAMs (number and/or 
phenotype) are part of the mechanism by which emodin reduces lung metastasis in the 
right tumor group. To determine the difference in TAMs content in left versus right 
emodin treated tumors, we first quantified the total number of TAMs (F4/80+ cells) in left 
versus right 4T1 tumors treated with emodin compared to the controls using flow 
cytometric analysis. Our results show that emodin treatment reduces TAMs percentage 
in right 4T1 tumors compared to the control (Fig. 4.2 a).  
 Then, we examined M1 versus M2 gene expression using qRT-PCR of TAMs 
isolated from emodin treated and control left versus right 4T1 tumors. Our data shows 
that in addition to the left versus right base line differences, M2 TAMs genes expression 
were significantly reduced in TAMs isolated from right emodin treated 4T1 tumors 
compared to TAMs isolated from left emodin treated 4T1 tumors (Fig. 4.2 b,c).      
This data suggests that emodin’s ability to reduce right tumor metastasis is modulated by 
reducing M2 TAMs in right tumors, consistent with what has been reported for emodin’s 
ability to target macrophages in the mammary tumor microenvironment (84).   
4.3.3. Emodin Treatment Reduces Cancer Stem Cells Population in Right 4T1 Tumors 
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 Given the important role cancer stem cells play in metastasis (180, 181), we 
hypothesize that emodin treatment differentially effects the cancer stem cell population 
in left versus right 4T1 tumors. To test this hypothesis, sphere forming efficiency (SFE), 
number of secondary spheres, and self-renewal were quantified for left versus right 
emodin treated 4T1 tumors compared to the controls. Our results show that in addition 
to base line differences in SFE in left versus right controls 4T1 tumors, right emodin 
treated 4T1 tumors have significantly lower SFE compare to right control 4T1 tumors. 
Emodin treatment has no effect on SFE of left 4T1 tumors (Fig. 4.3 a, b).  To determine 
the effect of emodin treatment on the self-renewal properties of cancer stem cells, 
secondary spheres and self-renewal ability were quantified. Our results show a significant 
reduction in the number of secondary spheres of right 4T1 emodin treated tumors but 
not the self-renewal compared to the controls (Fig. 4.3 c, d). No effect was found on SFE, 
number of secondary sphere, and self-renewal of left emodin treated 4T1 tumors 
compare to the left control 4T1 tumors (Fig. 4.3 b-d).  
 Taken together, our results indicate that emodin treatment reduces cancer stem 
cell content in right 4T1 tumors which then reduces the metastatic potential of right 4T1 
tumors. This result is consistent with what has been reported for emodin’s ability to target 
cancer stem cells (176, 177). Moreover, our results also show that emodin has no effect 
on cancer stem cell content in left 4T1 tumors. 
4.4. Discussion 
 Microarray analysis demonstrated that mammary glands exhibit left-right 
differences in gene expression, including genes associated with therapeutic response 
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(92). However, no existent study has determined if left versus right mammary tumors 
have different response to treatment.  Here, we use mouse models to show for the first 
time that left and right mammary tumors respond differentially to emodin treatment. 
Emodin is a natural compound isolated from several Chinese herbs that has been reported 
to have anti-cancer activity in different cancers including breast cancer (81, 84, 182, 183).  
 Our data demonstrates that emodin significantly inhibited lung metastasis of right 
4T1 tumors through modulating the tumors’ microenvironmental support. Emodin 
significantly reduces TAMs content and M2 TAMs gene expression in right 4T1 tumors. 
Increase evidence shows the critical role of TAMs in supporting metastasis through the 
promotion of invasion, migration, intravasation, and ECM remodeling (62, 65, 66). Our 
data here indicates that targeting TAMs content and polarization is part of emodin’s 
mechanisms to inhibit lung metastasis in right mammary tumors. 
 Our results also show emodin’s ability to reduce primary and secondary 
tumorsphere formation in right 4T1 tumors. This data suggests that emodin reduces 
cancer stem cells content in right mammary tumors which then inhibits metastatic 
development. Studies have shown that emodin can target cancer stem cells directly 
through Notch-1, β-catenin, and STAT3 signaling pathways (177). This data also suggests 
the indirect effect of emodin on cancer stem cells through its effect on TAMs which then 
effect cancer stem cells content in right mammary tumors. It has been reported that 
TAMs play a crucial role in regulating cancer stem cells in different cancers (169, 184). Our 
data indicates that emodin reduces lung metastasis in right 4T1 tumors group through 
targeting TAMs and cancer stem cells in tumor microenvironment.  Our results also 
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indicate that emodin has no effect on left 4T1 tumors metastasis, TAMs content, and 
cancer stem cells content.  
 Our data of left-right differences in mammary tumors therapeutic response 
suggests that women with breast cancer might have different responses to therapies 
based on their tumor situs. This data therefore also highlights the importance of laterality 





Figure 4.1: Emodin inhibits lung metastasis incidence and burden in mice bearing right 
4T1 tumors. (A) Upon sacrifice, number of mice with presence of lung metastasis by 
histological analysis were quantified for left versus right 4T1 DMSO and emodin treated 
groups. (B) Number of lung lesions in left versus right 4T1 DMSO and emodin treated 
groups. (C) Tumor volume of Left versus right 4T1 DMSO and emodin treated groups was 
monitored every three days using digital calipers (n=13). (D) Left versus right 4T1 DMSO 





Figure 4.2.: Emodin treatment decreases tumor-associated macrophages total number 
and M2 phenotype. (A) F4/80+ cells percentage in left versus right 4T1 DMSO and Emodin 
treated tumors. (B) SYBR Green-based RT-PCR analysis of IL-10 gene expression in TAMs 
isolated from left versus right 4T1 DMSO and Emodin treated tumors and (C) Arg-1 gene 
expression in TAMs isolated from left versus right 4T1 DMSO and Emodin treated tumors 




Figure 4.3.: Emodin quantitatively reduces cancer stem-like cells in right 4T1 tumors 
compared to left 4T1 tumors. (A) Representative images of tumor spheres from left 
versus right DMSO and Emodin treated groups. (B) Sphere Forming Efficiency (SFE) of 
primary sphere and (C) The number of secondary spheres from left versus right DMSO 
and Emodin treated 4T1 tumors shows that in addition to base line left versus right 
significant differences in the SFE, emodin treatment reduces the SFE of the right 4T1 
tumors but not the left 4T1 tumors. (D) Self-Renewal of left versus right DMSO and 
Emodin treated 4T1 cancer stem-like cells shows the base line left versus right differences 
and no effect by emodin treatment (* p<0.05) (** p<0.01).
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Chapter 5 
Conclusion and Future Perspective 
The proposed seed and soil hypothesis has significantly increased our current 
understanding of the role of cancer cells “seed” and the microenvironment “soil” in 
metastasis (140, 185). However, metastatic development is still the main cause of breast 
cancer mortality. That is in part because studies have been focusing only on the role of 
the stroma (19, 185, 186), and ignoring the other component of the mammary 
microenvironment, the epithelium. Failure to consider the role of the epithelial 
microenvironment may be a significant limitation in understanding and identifying 
metastatic regulators. This limitation is due the use of orthotopic mouse models in which 
tumor cells are incubated within the stromal microenvironment (fat pad), altogether 
bypassing the epithelium. Thus, the first aim of this study was to overcome this limitation 
by considering the role of the epithelium in breast cancer progression and metastasis 
using 4T1 mouse model. 
By using the intraductal injection, we were able to consider the role of the 
epithelium in 4T1 tumor progression and metastasis. Our results, chapter 2, confirmed 
that the epithelial microenvironment supports more aggressive 4T1 tumors compared to 
4T1 tumors generated within the stroma. Our result showed that including the epithelial 
microenvironment causes changes in 4T1 tumor properties, including: faster growth rate, 
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more aggressive histopathology, and earlier metastatic development, compared to 4T1 
fat pad generated tumors. Moreover, RNA-sequencing analysis revealed molecular 
changes in 4T1 cells after intraductal incubation when compared to non-injected 4T1 
cells. Furthermore, the RNA-Sequencing analysis identified multiple pathways that are 
associated with more aggressive 4T1 cells and have not been reported in 4T1 fat pad 
generated tumors. Together, these results show the epithelial microenvironment’s ability 
to support more aggressive 4T1 tumors compared to the stromal microenvironment 
which will open up new avenues in studying metastatic regulators.  
Another unappreciated factor that might limit our understanding of metastatic 
regulators is the tumor situs. Mammary glands develop as paired organs, and it has been 
demonstrated that left and right mammary glands exhibit different molecular profiles 
(92). Moreover, some of left versus right differentially expressed genes are associated 
with tumorigenesis and therapeutic response (92). Furthermore, epidemiological studies 
have shown left-right difference in tumor aggressiveness and patients’ survival rate (90, 
93, 187). These findings suggest that there may be left-right differences in tumor biology 
which further suggest that there are differences in left versus right microenvironmental 
support of tumorigenesis. Therefore, we investigated if left versus right mammary 
microenvironments differentially support tumor progression and metastasis.  
Our results, chapter 3, demonstrated for the first time that left versus right 
mammary microenvironments form 4T1 tumors with different properties including: 
tumor histopathology, 4T1 gene expression, macrophage polarization, and metastatic 
behavior. The right mammary microenvironment promotes more advanced 4T1 tumor 
88 
histopathology with greater muscle invasion and collagen deposition compared to the left 
microenvironment. Our results also revealed the right microenvironment’s ability to alter 
4T1 gene expression. RNA-Sequencing analysis showed that the genes that are up-
regulated in 4T1 cells isolated from right tumors are associated with more aggressive 
disease progression such as MMPs, Wnt, and several genes from the COL and Hox families 
(68, 132, 156, 163). In 4T1 cells isolated from left tumors, upregulated genes are 
associated with enhanced anti-tumor immunity, such as CCL12, CXCL13, and CD226(164-
166). These results indicate the role of left versus right mammary microenvironments in 
engineering cancer cells which then impact their metastatic activity. Moreover, TAMs 
polarization was different in left versus right tumors. While the total TAMs number was 
the same in left and right microenvironments, the right tumors had a greater percentage 
of M2 TAMs. Furthermore, our results showed that 4T1 tumors generated in the right 
microenvironment have greater metastatic incidence and more lung lesions. 
Taken together, our results in chapter 3 showed for the first time that the right 
mammary microenvironment promotes more M2 tumor-associated macrophages which 
promote more aggressive 4T1 cells and increased metastatic behavior. These results 
indicate the importance of tumor situs in tumor progression and metastasis not only in 
the perspective of mouse models but also in clinical analysis of breast cancer patients. 
Thus, considering tumor situs when studying breast cancer will uncover unappreciated, 
molecular and/ or cellular, changes that contribute to metastatic development. 
Our results for left-right differences in the microenvironmental support of cancer 
cells suggest left-right differences in therapeutic response. Our results showed that the 
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right microenvironment promotes more M2 TAMs compare to left microenvironment. 
This result lends support to the hypothesis that left-right mammary microenvironments 
can respond differently to emodin treatment. Emodin is the active ingredient of several 
Chinese herbs and has been used for a long time to treat inflammatory disease (74). 
Emodin has furthermore been found to have anti-cancer properties, which makes it a 
potential cancer therapy. Emodin toxicity towards cancer cells is accomplished through 
targeting  different signaling pathways such as NFκB, ERK 1/2, p38, JUNK and PI3K/AKT in 
different cell lines(78). Moreover, studies have reported that emodin can effect tumor 
microenvironment and inhibit tumor growth and metastasis through its effect on TAMs 
polarization and M2 TAMs recruitment to the lung (77, 84, 85).   
Our results, chapter 4, indicated for the first time that left and right mammary 
tumors have a different therapeutic response to emodin. Emodin inhibits lung metastasis 
incidence and burden in mice bearing right side 4T1 tumors, while having no effect on 
mice bearing left 4T1 tumors. Our results showed that emodin also reduces the total 
number of TAMs in right tumors. Moreover, our PCR results showed that emodin 
treatment reduces M2 TAMs in right 4T1 tumors. Furthermore, emodin treatment was 
able to reduce cancer stem cells population in right 4T1 tumors. These results indicate 
that emodin treatments inhibits the support of the right microenvironment to metastatic 
activity and this inhibition is modulated through targeting TAMs, ultimately effecting the 
CSCs population.   
Our results demonstrated for the first time that left and right mammary 
microenvironments differentially support tumor progression, metastasis, and therapeutic 
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response. This indicates the importance of considering tumor laterality in the study of 
breast cancer not only in preclinical mouse models but also in patients’ data analysis. 
Laterality could be used as a tool to further understand metastatic regulators in breast 
cancer. More studies are needed to further understand the mechanism by which the right 
mammary microenvironment supports the growth of more aggressive tumors. 
Furthermore, the data presented in this project indicates the importance of laterality to 
be studied in other cancers that originate in paired organs.
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